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Abstract: Marine micro- and macroorganisms are well known to produce metabolites with high
biotechnological potential. Nearly 40 years of systematic prospecting all around the New Caledonia
archipelago and several successive research programs have uncovered new chemical leads from
benthic and planktonic organisms. After species identification, biological and/or pharmaceutical
analyses are performed on marine organisms to assess their bioactivities. A total of 3582 genera,
1107 families and 9372 species have been surveyed and more than 350 novel molecular structures
have been identified. Along with their bioactivities that hold promise for therapeutic applications,
most of these molecules are also potentially useful for cosmetics and food biotechnology. This review
highlights the tremendous marine diversity in New Caledonia, and offers an outline of the vast
possibilities for natural products, especially in the interest of pursuing collaborative fundamental
research programs and developing local biotechnology programs.
Keywords: New Caledonia; marine biodiversity; bioactive molecules pipeline; chemodiversity;
coral reefs
1. Introduction
Located approximately at 165˝ E and 21˝301 S, the New Caledonia archipelago enjoys a privileged
position east of the city of Rockhampton, central province of the Great Barrier Reef, 1500 km away
from the Australian Queensland coast, with surface seawater temperatures mild enough to avoid
recurrent coral bleaching episodes.
This tropical subregion of Melanesia is a relic of a continental landmass that drifted away from
the super-continent Gondwana at the end of the Cretaceous period (see Pelletier 2007) [1]. Successive
geological events have resulted in an archipelago that comprises a main island called Grande Terre, Ile
des Pins in the south, the Entrecasteaux reefs in the north, the Loyalty Islands in the east and, finally,
the Chesterfield-Bellona plateau in the west, located at mid-distance to Australian coast (Figure 1).
New Caledonian waters represent an exclusive economic zone (EEZ) spanning more than
1,700,000 km2. The EEZ includes a vast and complex reef system of 4537 km2 of reef area and
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31,336 km2 of non-reef area [2] and represents the second most important coral reef complex and the
longest continuous barrier reef in the world, stretching over 1600 km.
The reef systems together make up a unique marine ecosystem [3] with more than 161 different
reef units [4] supporting high marine species diversity and abundance [5], including so-called “living
fossils” such as a stalked crinoid and a shelled cephalopod.
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Figure 1. The archipelago of New Caledonia and its reef complexes (adapted from Andréfouët et al.
2009 [2], with kind permission from the author).
Only since the 19th century has attention been paid to diversity of the New Caledonian reef
systems. Many expeditions have been conducted to st dy the ocea ic life of hese hitherto unexplored
oceanic zon s. The first oceanographic cruise, the Challe ger expedition (1872–1876), led to the collection
of thousands of previously unknown marine species [6]. Since the 19th century, scientific interest has
shifted from the study of “exotic” specimens stored in museum collections and classified according to
their morphological features, to the study and understanding of marine ecosystems. Charles Darwin’s
landmark expeditions in the Eastern Pacific islands and his remarkable observations on the formation
of atolls from subsiding volcanic islands sparked continued int rest in ecosystems biol gy in oceans
across the world. Research vessels are now equipped with sophisticated equipment to carry out on-site
sample analysis (e.g., molecular biology) and data transmission via satellite systems. For example, the
schooner Tara, specially fit out with on-board facilities, recently sailed around the world to study the
impact of global warming on plankton and coral reef systems across the Pacific [7].
Pioneeri g scientific investigati ns in New Caledonian waters were carried out locally after
World War II. The naturalist René Catala initiated ecological surveys and species census around Ile aux
Canards [8], an island off Nouméa now directly exposed to human activities, with recent changes in reef
zonation and species composition. In addition, in 1956, Catala founded the Aquarium of Nouméa (now
the Aquarium des Lagons), a first-of-its-kind structure specifically designed to observe rare and fragile
marine species in their environment, including homegrown corals. Catala incidentally discovered the
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fluorescence of living corals [9] and other invertebrates (fluorescence appears to be a photoprotective
and possibly temperature-regulating mechanism). A few years later, the Singer-Polignac expedition
(1960–1963) explored St. Vincent Bay and the east coast of Grande Terre [10–12]. Similarly, the American
ecologist, Arthur Lyon Dahl, a regional adviser at the South Pacific Commission from 1974 to 1982,
demonstrated the importance of surface area in ecological analysis and described several methods for
conducting surveys of coral reefs [13,14].
Bioprospecting studies in New Caledonia were initiated in 1976 by Pierre Potier from the ICSN
(Institute of Natural Substances Chemistry, Gif-sur-Yvette, mainland France) as part of the national
research program SNOM (Substances Naturelles d’Origine Marine) and benefited from collaboration
with scientific divers from IRD (Institut de Recherche pour le Développement, ex. ORSTOM, Office de la
Recherche Scientifique et Technique d’Outre-Mer) in Nouméa (Figure 2). SNOM set out to explore marine
biodiversity extensively with the taxonomic expertise from the National Museum of Natural History
(MNHN) of Paris, to identify novel molecules and to assess their biological activities primarily for
pharmaceutical purposes. Collecting efforts focused mainly on invertebrates, including octocorals,
porifers, echinoderms, mollusks and ascidians. Little attention has been given to macroalgae due to
the lack of taxonomic support.
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Figure 2. Publications in scientific journals on organisms collected within various research programs.
Cumulative data representing the total number of publications generated since 1976 to present (red line)
and the number of publications produced per year since 1976 (blue line). The timeline on the x-axis
shows the various regional marine biodiversity programs spanning the 40-year period. These statistics
do not include reports, reviews and book chapters. The insert shows the relative percentages of major
taxon investigated up to 2007 [5]. SNOM: Substances Naturelles d’Origine Marine; SMIB: Substances
Marines d’Intérêt Biologique; LAGON; MUSORSTOM (now Tropical Deep-Sea Benthos): acronym
for the joint expeditions of the National Museum of Natural History (MNHN) and the Office de la
Recherche Scientifique et Technique d’Outre-Mer (ORSTOM, now IRD); CRISP: Coral Reef InitiativeS for the
Pacific; in progress: various research programs including chemical and pharmacological investigations
on micro- and macroalgae. Fl/Ma: Flora and Marine Angiosperms; Pro: Protozoa; Alg: Algae;
Por: Porifera; Cni: Cnidaria; Loph: Lophophorates; Mol: Mollusks; Wor: Worms; Art: Arthropoda;
Ech: Echinodermata; Tun: Tunicata; Ver: Vertebrata.
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In 1985, the SNOM program was followed by the SMIB program (Substances Marines d’Intérêt
Biologique), which was conducted jointly by ORSTOM and the Centre National de la Recherche Scientifique
(CNRS), with a large collaborative network of public research institutions, e.g., the Centre d’Etudes Nucléaires
de Saclay, the Institut National de la Santé et de la Recherche Médicale (INSERM), the MNHN, French and
foreign universities, as well as several private companies (in particular, Pierre Fabre and Rhône-Poulenc).
The raw compounds and their fractions were extracted at the ORSTOM center in Nouméa and
were originally sent for purification and structural determination to the ICSN (mainland France), and the
biological screening was assigned to various mainland French laboratories. Gradually, separation and
purification, as well as preliminary testing and benchtop assays, were carried out locally in New Caledonia
at the ORSTOM (and later IRD) center, to avoid unnecessary duplication and to better target specific
requests from collaborating partners. During this time, a number of candidate molecules were identified
for their anticancer, cardiovascular or neurological interest (reviewed in [15]), prompting an extension of
the research program and redefinition of the terms of scientific collaboration, now open to international
experts. The purchase of a larger research vessel, the R/V Alis, in 1992, provided the opportunity to extend
the bioprospecting range by dredging to 600 m deep and to access new biological resources.
The SNOM and SMIB programs led to an extensive survey of the marine biodiversity of the
New Caledonian archipelago, providing many in situ observations and records of new taxon, which
have been published in several papers [5] and illustrated in field guides, especially on sponges [16],
echinoderms [17], gorgonians [18], ascidians [19], marine snakes [20], and fishes [21]. Among the 300
organisms studied, only 50 have been the object of chemical and therapeutic research and several
original molecules have been described and tested on tumor development [22].
After the SNOM and SMIB programs, pharmacological bioprospecting in New Caledonia was
integrated in the LAGON and MUSORSTOM biodiversity projects until 2000. Thereafter, research
activities were extended to other countries in the Pacific region as part of the Coral Reef InitiativeS for
the Pacific (CRISP), with emphasis on legal agreements and economic benefits to host countries.
In the meantime, some research activity focused on ciguatera and cyanobacteria toxicity after
several severe poisoning events occurred in New Caledonia. In addition to pharmaceutical activities,
natural marine compounds inspired new scientific approaches including chemotaxonomy and
chemical ecology of benthic macroalgae to understand how opportunistic algae colonize living
coral. These activities are conducted by the CoReUs/ENTROPIE research team at IRD (Figure 2).
These projects are mentioned in Moretti et al., (1993) [22] and detailed in a comprehensive review of
novel chemical structures and associated pharmacological activities described by Laurent and Pietra
published in 2004 [15]. Another review emphasizes the developmental aspects of marine molecules
from South Pacific zone including New Caledonia [23].
Here, we provide an updated review of 40 years of exploration of the marine micro-/macrophyte
and invertebrate chemodiversity of this species-rich zone of the Southwest Pacific, with its
pharmacological potential and its ecological significance. After a description of the basic operational
aspects of discovering marine natural products, an overview of the work on each major taxon is
presented, illustrated by case studies that have been the highlights of the abovementioned programs
for the last 40 years, and carried out locally by experts in full compliance with existing regulations of
biodiversity protection and the sustainability of valuable natural resources.
2. Taxonomy
SCUBA diving allows visual exploration of shallow-water marine biota, making it possible not
only to collect material at depths down to 60 m, but also to take photographs and record ecological
information, e.g., interactions between organisms that can be useful for selecting organisms to collect
and subsequent biological tests. Upon the development of blind transect dredging with limited
biomass sampling on soft bottoms, collection efforts were extended to deeper zones (down to 600 m),
thus sampling entirely different organisms.
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2.1. Sample Collection Sites
Collection sites were selected to cover the large diversity of habitats ranging from shallow lagoons
to deep parts of the outer slopes of the barrier reefs. They include hard and sandy bottoms, sheltered
and exposed areas of the mainland (Grande Terre), Loyalty Islands, as well as remote reefs and atolls
(Entrecasteaux, Chesterfield) and seamounts (Figure 1).
Each site was georeferenced and described using geomorphological and biological descriptors.
Historical data have been sorted, standardized and stored along with recent information in the
dedicated database LagPlon [24].
2.2. Biological Material Sampling
For all the groups collected for chemical purposes, specimens from each taxon were sampled
for taxonomical identification and preserved in ethanol as vouchers after labelling. Collections were
duplicated, one sample was kept for the IRD reference collection to facilitate new sampling efforts
and the duplicate was sent to specialists for taxonomy work. In situ macrophotographs were taken as
well as additional ex situ laboratory photographs when necessary. Specimens used to describe new
species (holotypes) have been deposited in various museum collections in Australia (Northern Territory
Museum, Darwin and Queensland Museum of South Brisbane), New Zealand, mainland France (National
Museum of Natural History, Paris), Belgium (Université Libre de Bruxelles). Paratypes were systematically
filed in the IRD reference collection in Nouméa, along with photographs and field records.
3. Chemistry
3.1. Biological Material
Chemical characterization and biological assays were initially carried on samples with wet
weights ranging from 300 to 3000 g. However, recent progress in analytical techniques allows molecular
inventory and pharmacological tests from smaller amounts of material in compliance with international
regulations on the use of biological material for research purposes.
Below, we describe the basic protocols used locally at the IRD laboratories in Nouméa. Each of the
molecules that have been investigated locally or with national and international partners have been
treated separately (Figure 3). It is beyond the scope of this review to detail each protocol individually;
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Figure 3. Collaborative network of chemists and pharmacologists from 1976 to 2013 as compiled
individually from journal publications.
3.2. Conditioning Samples for Chemistry
Freshly collected material is sorted by taxon and frozen on board at ´20 ˝C, or at least placed
in 70% ethanol in distilled water (slightly acidified to avoid oxidation of polar compounds) until it
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can be deep frozen and freeze-dried for subsequent use. Material used for enzymology or genome
studies is snap-frozen on board (liquid nitrogen or dry ice in pure alcohol). For short collecting sessions
(less than one full day), the material may be kept alive if each item is appropriately handled.
Back at the laboratory, the material must be ground/chopped/crushed then freeze-dried or
ethanol-preserved and stowed away for later use, or sent abroad to partner laboratories.
3.3. Extraction
3.3.1. Routine Procedure
Unless otherwise specified, a standard protocol is used for extracting compounds and separating
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Figure 4. Routine extraction protocol (IRD Nouméa).
Organic fractions ar generally evaporated under vac um (Rotovap) and kept in the dark at
´20 ˝C. Water solubles may need to be desalted using size- xclusion gel chromatography (SEC) or by
membrane filtration under nitrogen (Amicon®, Alsace, France) prior to separation, but for long-term
storage, desalting is not necessary. Aliquoting is necessary for multiple chemical characterizations and
for bioassays.
3.3.2. Peptide Protease Inhibitors
Live tissues are processed ( inced or fragmented) on boar and placed in n acidic solution
(methanol/2 N acetic acid) to optimize the extraction of polar substances and block any potential
hydrolysis by proteolytic enzymes. The cold (´20 ˝C) slurry is filtered twice and filtrates are reduced
by evaporation and neutralized to pH 5.5 prior to freeze-drying. The total protein content of the crude
extract is assayed by measuring optical densities with a UV spectrophotometer.
3.4. Separation, Purification
Classical separation and purification techniques (TLC, HPLC, SEC) were not routinely used unless
requested for products presenting an interesting bioactivity profile. This data is mentioned in the
original publications for each novel structure.
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3.5. Structural Analysis
Basic spectroscopic (NMR, UV, IR) and spectrometric (MS) methods are used when available on
site, mostly to avoid replication.
3.6. Chemical Databases
The IRD proprietary information system Cantharella [25] compiles pharmacochemical data of
all organisms collected in New Caledonia and cross-Pacific oceanographic cruises for the study of
their natural substances, with restricted access via Internet. The information system provides access to
biological data, accounts for all chemical processes from extraction to purification, and presents the
bioactivity profile detected using the complete range of tests.
4. Biological Activities
4.1. Preliminary Testing
Vacuum-dried crude extracts or non-purified fractions thereof can be used for describing general
characteristics using toxicity assays on various invertebrate, vertebrate and plant models, and cultures
of microbial reference strains (Table 1).
Preliminary tests performed on site are useful for making appropriate decisions as to whether a
given sample from a newly collected organism is worth investigating further. Along with taxonomic
criteria and dereplication issues, such decisions are now taken after consulting the scientific literature
and specialized databases, especially the IRD databases LagPlon [24] and Cantharella [25], which, in
addition to the more traditional MarinLit and other databases, considerably aid local researchers.
Table 1. Field observations and crude biological tests for preliminary screening.
Biological Model Species Type of Activity Tested Reference
Bacteria
Escherichia coli, Pseudomonas aeruginosa,
Staphylococcus aureus, Streptococcus










Brine shrimp larvae Artemia salina Cytotoxicity [27]
Fish Gambusia affinis Neuro/Cytotoxicity [28,29]
Urchin eggs Echinometra mathaei Cytotoxicity [30]
Insect Hypothenemus hampei Insecticide [31]
Mite Rhipicephalus microplus (formerly,
Boophilus microplus) Acaricide [32]
Algae Ceramium codii Anti-fouling [33]
Coral Algae Allelopathy [34]
Plant Amaranthus caudatus Anti-germinating [35]
4.1.1. Brine Shrimp Toxicity Assay
The brine shrimp (Artemia salina) toxicity bioassay is one of the most basic and widely used tests
to detect cytotoxicity. Newly hatched brine shrimp nauplii are exposed to various concentrations of
soluble or solubilized test substances and mortality is recorded, leading to a median lethal dose (LD50)
estimate. A typical protocol is detailed in [27].
4.1.2. Mosquito Fish Toxicity Assay
The mosquito fish Gambusia affinis is often used to evaluate the toxicity of substances to be
screened for antimitotic activities, and it has been adapted from [28], a study that used this species for
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comparative ecotoxicological studies of soft corals. The mosquito fish toxicity test has been extended
to include multiparametric behavioral observations and can provide valuable neurophysiological
information as well as ecotoxicological data on crude extracts that are water soluble or solubilized [29].
4.1.3. Fertilization of Sea Urchin Eggs
The aim of this test is to observe the division pattern of eggs of the test sea urchin Echinometra mathaei
fertilized in the laboratory, by adapting the method Kobayashi [30] originally designed for testing the
toxicity of heavy metals on early embryonic stages. This test is highly sensitive and works at extremely low
concentrations of the test substances. Cell division arrest at specific early and embryonic stages provides a
preliminary indication of specific enzymatic inhibition at determined steps of the cell cycle.
4.1.4. Anti-Serpin Activity
Serine protease inhibition assays are conducted locally using bovine trypsin (protocol inspired
from Green et al., 1953) [36] and porcine elastase [37], with respectively, benzoyl-arginine ethyl ester
(BAEE) and succinyl (Alanyl)3 para-nitro anilide (Suc [Ala]3 pNa) as substrates. End-point titration
using pH-stat benchtop equipment is used to evaluate the inhibition potential of the crude extracts on
bovine trypsin. The colorimetric method is used to evaluate the anti-elastase activity of the crude extracts.
4.2. Further Biological Testing
For the identification of antiproliferative natural products, cancerous and non-cancerous
mammalian cell lines are tested. The comprehensive list of cell lines that are used to characterize active
molecules from sponges is given in the footnote of Table 2.
Following the preliminary anti-serpin tests (see Section 4.1.4.), other serine proteases
(chymotrypsin, subtilisin), cysteine proteases (papain, viral proteinases), aspartic proteases (pepsin,
renin) and metalloproteases (thermolysin, carboxypeptidase A) have been carried out by M.A.
Coletti-Previero, Montpellier (mainland France).
5. Natural Products by Taxon
5.1. Porifera (Sponges)
5.1.1. General Comments
Sponges are multicellular, filter-feeding diploblastic invertebrates, i.e., without organized tissues
or organs, but with a special inner layer of ciliated cells called choanocytes that generate constant water
flow through numerous feeding/excretory channels. There are two major subphyla of Porifera based on
their biomineralization patterns: the Calcarea or calcareous sponges and the Silicispongia or siliceous
sponges, the latter group being further subdivided into Hexactinellida (glass sponges), Demospongiae,
which contain a proteinaceous matrix (spongin), and Homoscleromorpha, now recognized as distinct
from the latter class. Calcareous sponges are primarily found in shallow waters, and particularly
abundant and diverse in tropical coral reefs. Siliceous sponges, which represent most of the living
sponge species today, are found at all bathymetric levels and also in freshwater, with large populations
in some rivers and lakes. Most glass sponges live in deep waters, and are difficult to access [16].
Since the 1980s, deep-water dredging on the outer reef slope of the barrier reef down to 800 m has led
to the discovery of a number of non-described species. As of 2007, 149 species of Porifera have been
recorded in New Caledonian waters [5].
Most shallow-water sponge species live in symbiosis with Archaea, eubacteria and cyanobacteria,
forming holobiont systems that represent the main source of bioactive compounds [38,39] primarily
isolated from host tissues, but occasionally isolated from cultures of associated microbiota. Sponges
contain a wide range of so-called secondary metabolites, some of which afford interesting biological
activities [40] (Table 2).
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Table 2. Natural products isolated from New Caledonian sponges and their bioactivity.
Natural Product Chemical Class Biological Activity Species Reference
agelastatin A unusual C11 alkaloid antiproliferativekinase inhibitor
IC50 (µg/mL) KB 0.075, L1210 0.033






Active on SRIF 2.21 µM (Ki 2.47 µM);
VIP 19.8 µM (Ki 63.8 µM). Agelas novaecaledoniae [45]




IC50 (µg/mL) P388 < 3.3, NSCLC-N6 < 1.1, NSCLC-N6 C15 > 30,
NSCLC-N6 C92 < 3.3, NSCLC-N6 C98 < 3.3, E39 < 1.1, M96 < 3.3
Callipelta sp.
[46,47]antiviral
Day 6 post-infection: CD50 0.29 µg/mL and ED50 HIV-1 0.01 µg/mL
(SI 29), AZT reference CD50 50 µM and ED50 30 nM.
antifungal Ca 30 mm/100 µg/disk.
callipeltin B antiproliferative antiviral
IC50 (µg/mL) P388 < 3.3, NSCLC-N6 1.3, NSCLC-N6 C15 22.5,
NSCLC-N6 C92 > 30, NSCLC-N6 C98 < 3.3, E39 > 10, M96 < 3.3
Inactive against HIV-1.
[47]
callipeltin C acyclic depsidecapeptide antiproliferativeantifungal antiviral
IC50 (µg/mL) NSCLC-N6 53.5, E39 36.1







IC50 (µg/mL) P388 15.26, NSCLC-N6 11.26
G1 cell cycle arrest in NSCLC-N6 cells. [48]
callipeltoside B
antiproliferative
IC50 NSCLC-N6 15.1 µg/mL.
[49]
callipeltoside C IC50 NSCLC-N6 30.0 µg/mL.
corallistin A porphyrin antiproliferative IC50 KB 10 µg/mL.Inactive in vivo and in tubuline assay. Corallistes sp. [50,51]
coscinosulfate sulfated sesquiterpene antiproliferativeantimitotic antibacterial
Against Jurkat and HBL100 cells (data not shown).
CDC25A inhibitor: IC50 3 µM.
Sa 12 mm/50 µg/disk.
Coscinoderma mathewsi [52]





girolline degraded C11 alkaloid
antiproliferative
antimalarial
IC50 (µM) P388 0.06, P388/Dox 0.08, KB 0.21, T24 0.19
IC50 Pf 77-215 nM.
[54–57],
[58–62]
pyraxinine 3-pyridylguanidine anti-inflammatory Inhibition of macrophagic NO synthase at 100 µM. [63]
hymenialdisine tricyclic pyrrole alkaloid kinase inhibitor IC50 (nM) CDK1/cyclin B 22, CDK2/cyclin A 70, CDK2/cyclin E 40,CDK5/p25 28, GSK-3β 10, CK1 35 and PLK-1 10,000. [44,64]
methyl diacarnoate A
epi-dioxy norditerpene







IC50 7.4 and 7.2 µM on CQ-sensitive and CQ-resistant Pf, resp.
IC50 KB >> 20 µg/mL.
[65,66]
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Table 2. Cont.
Natural Product Chemical Class Biological Activity Species Reference
2-epimukubilin benzyl ester
epi-dioxy norsesterterpene antiproliferative
IC50 KB 1.0 µg/mL.
[65]
methyl prenyldiacarnoate A IC50 KB 3.3 µg/mL.
methyl
2-epiprenyldiacarnoate A IC50 KB 0.9 µg/mL.
nortopsentin D bis-indole alkaloid antiproliferative EC50 KB 0.014 µg/mL (permethylated derivative). Dragmacidon sp. [67]
arsenicin A polyarsenic antibacterial antifungal 10 µg/disk, Sa/Ec/Ca: 24/28/26 (mm) for arsenicin A, and 22/30/22(mm) for gentamicin. Echinochalina bargibanti [68]
euryspongiol A1 polyhydroxylated
9,11-secosterol antihistaminic
Reduction of histamine release by 26% (control 35%). Euryspongia sp. [69]




IC50 HIV-1 75 nM. IC50 (nM) KB 7.3, MCF-7 23.6, MCF-7R 22.9,
HCT116 6.0, HCT15 22.5, HT29 70.0, OVCAR8 5.4, OV3 7.5, PC3 4.2,
Vero 5.0, MRC5 11.0, HL60 24.1, HL60R 22.4, K562 24.0, PaCa 31.4,
SF268 9.9, A549 8.3, MDA231 10.9, MDA435 39.0, HepG2 68.6, EPC 5.0
Homophymia sp.
[70,71]
homophymine B antiproliferativemechanism of action
IC50 (nM) KB 18.0, MCF-7 16.8, MCF-7R 26.3, HCT116 13.8, HCT15
22.9, HT29 101.9, OVCAR8 8.0, OV3 9.9, PC3 6.2, Vero 8.6, MRC5 17.1,
HL60 43.1, HL60R 36.7, K562 26.7, PaCa 62.0, SF268 17.2, A549 19.8,
MDA231 17.0, MDA435 40.1, HepG2 99.0, EPC 8.0.




IC50 (nM) KB 8.5, MCF-7 8.8, MCF-7R 10.8, HCT116 4.9, HCT15 19.2,
HT29 62.8, OVCAR8 4.3, OV3 3.7, PC3 3.0, Vero 4.2, MRC5 16.8, HL60
23.0, HL60R 23.5, K562 22.5, PaCa 25.9, SF268 13.6, A549 8.3, MDA231
16.2, MDA435 35.0, HepG2 72.1, EPC 9.3
homophymine D
IC50 (nM) KB 12.7, MCF-7 19.6, MCF-7R 37.7, HCT116 19.8, HCT15
43.2, HT29 81.3, OVCAR8 8.1, OV3 10.6, PC3 6.3, Vero 10.9, MRC5 16.9,
HL60 29.6, HL60R 24.9, K562 35.3, PaCa 37.4, SF268 17.9, A549 13.8,
MDA231 18.9, MDA435 49.9, HepG2 78.7, EPC 11.1
homophymine E
IC50 (nM) KB 6.0, MCF-7 14.2, MCF-7R 15.6, HCT116 5.5, HCT15 27.2,
HT29 35.1, OVCAR8 4.6, OV3 4.2, PC3 3.9, Vero 7.0, MRC5 9.5, HL60
23.3, HL60R 21.4, K562 22.2, PaCa 18.1, SF268 8.1, A549 9.6, MDA231
13.3, MDA435 38.3, HepG2 60.5, EPC 9.5
homophymine A1
IC50 (nM) KB 7.1, MCF-7 12.4, MCF-7R 13.5, HCT116 6.1, HCT15 13.5,
HT29 30.9, OVCAR8 5.1, OV3 5.5, PC3 3.7, Vero 6.1, MRC5 7.8, HL60
17.3, HL60R 11.1, K562 12.8, PaCa 19.2, SF268 6.3, A549 6.0, MDA231
8.4, MDA435 27.0, HepG2 91.4, EPC 7.8
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IC50 (nM) KB 16.4, MCF-7 14.2, MCF-7R 12.3, HCT116 11.4, HCT15
14.1, HT29 93.8, OVCAR8 6.5, OV3 8.0, PC3 4.7, Vero 6.1, MRC5 10.2,
HL60 18.7, HL60R 25.8, K562 16.6, PaCa 22.2, SF268 11.7, A549 8.6,
MDA231 18.2, MDA435 29.5, HepG2 100.3, EPC 6.6
Homophymia sp. [71]
homophymine C1 antiproliferativemechanism of action
IC50 (nM) KB 6.8, MCF-7 6.3, MCF-7R 5.4, HCT116 2.7, HCT15 17.2,
HT29 38.2, OVCAR8 2.6, OV3 2.4, PC3 2.6, Vero 3.1, MRC5 8.0, HL60
14.6, HL60R 17.1, K562 11.9, PaCa 14.4, SF268 7.1, A549 6.2, MDA231
15.8, MDA435 20.3, HepG2 58.6, EPC 12.2 Caspase-independent cell
death pathway (HL60).
homophymine D1 antiproliferativemechanism of action
IC50 (nM) KB 10.6, MCF-7 3.5, MCF-7R 3.5, HCT116 1.8, HCT15 11.4,
HT29 32.2, OVCAR8 1.6, OV3 1.4, PC3 1.4, Vero 1.8, MRC5 10.5, HL60
13.1, HL60R 21.9, K562 12.9, PaCa 17.6, SF268 7.9, A549 5.0, MDA231
11.1, MDA435 23.4, HepG2 80.4, EPC 7.7 Caspase-independent cell
death pathway (HL60).
homophymine E1 antiproliferative
IC50 (nM) KB 12.5, MCF-7 3.9, MCF-7R 7.1, HCT116 2.3, HCT15 10.1,
HT29 31.8, OVCAR8 4.0, OV3 2.7, PC3 3.5, Vero 4.4, MRC5 12.3, HL60
20.5, HL60R 23.2, K562 17.8, PaCa 10.6, SF268 10.1, A549 11.4, MDA231




Inactive on farnesyl transferase. Hyrtios erecta [72,73]
heteronemin IC50 3 µM. Hyrtios reticulata [73]
thorectolide
terpene




IC50 KB 0.3 µg/mL.






IC50 KB 0.8 µg/mL.
Ct 12 mm/50 µg/disk.
Sa 12 mm/50 µg/disk.
IC50 (µg/mL) Pf F32 0.6, FcB1 2.1 and PFB 1.5
[75,76]
dipuupehedione antiproliferativeantifungal antibacterial








IC50 KB 6 µg/mL.
Sa 7 mm/1 µg/disk.
Ct 9 mm/50 µg/disk.
IC50 (µg/mL) Pf F32 0.4, FcB1 1.4 and PFB 1.2
[76]
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IC50 TPK 8 µg/mL.




IC50 TPK 4.0 µg/mL.
heptaprenylhydro-quinone





IC50 (µg/mL) KB 0.05, P388 0.25
Ca 26 mm/40 µg/disk.
Leucascandra caveolata
[78]
leucascandrolide B IC50 (µg/mL) KB 5, P388 >10Inactive against Ca. [79]
microsclerodermin A






IC50 (ng/mL) NSCLC-N6 27, P388/Dox 0.33, P388 4.1, KB 7.0,
HT29 115




IC50 (ng/mL) KB 0.03, P388 3.1, P388/Dox 0.02, NSCLC-N6 16,
HT29 2.4
IC90 values < 2 ppm against Pc, Pci, Pr, Pv, Bc, Po, Fr, Aa, Rs, Ph, Sn,
Hg and Un.
sphinxolide C
IC50 (ng/mL) KB 40, P388 40, P388/Dox 30, NSCLC-N6 30, HT29 30




IC50 (ng/mL) NSCLC-N6 60, P388/Dox 8, P388 3, KB 3.0, HT29 22 [81]
sphinxolide E NCI screening: 60 human cell lines (9 cancer types: leukemia, lung,
colon, brain, melanoma, ovarian, renal, prostate and breast).
Sphinxolides F and G: less potent by 10-100 times compared to E. Same
degree of cell line selectivity.
[83]sphinxolide F
sphinxolide G
superstolide A IC50 (µg/mL) KB 0.02, P388 0.003, P388/Dox 0.02, NSCLC-N6-L160.04, HT29 0.04 [84]
superstolide B IC50 (µg/mL) KB 0.005, P388 0.003,SCLC-N6-L16 0.039 [85]
neosiphoniamolide A cyclic depsipeptide antifungal IC90 Po and Hg 5 ppm, > 5 ppm against Pc, Pci, Pr, Pv, Bc, Fr, Aa, Rs,Ph, Sn and Un. [82]
nepheliosyne A C47 polyoxygenated
acetylenic acid
antiproliferative
IC50 (µM) K562 200, U266 170, SKM1 250, Kasumi 200 Niphates sp. [86]
nepheliosyne B IC50 (µM) K562 150, U266 200, SKM1 > 250, Kasumi 150
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Natural Product Chemical Class Biological Activity Species Reference
gelliusine A racemic tris-indole
alkaloid




Serotonin agonist (10-100 µM).
SRIF (100% displacement) and NPY (90%) active at 5 µg/mL.
Bradykinin receptor 100%.
Inactive on NK3, AMPA, CGRP, galanin, glycine, NT and
VIP-binding assays.
gelliusine B racemic tris-indolealkaloid
serotoninergic activity
Bradykinin receptor 93% and NPY 62%.








Inactive on serotonin receptor.
SRIF (87% displacement) active at 5 µg/mL. NPY 63% and bradykinin
receptor 63%.




Inactive on serotonin receptor.
SRIF (91% displacement) active at 5 µg/mL.
Bradykinin receptor 89% and NPY 67%.






IC50 NSCLC-N6 13.0 µg/mL.
Petrosaspongia nigra
[89]
petrosaspongiolide B IC50 NSCLC-N6 14.8 µg/mL.
petrosaspongiolide C IC50 NSCLC-N6 0.5 µg/mL.
petrosaspongiolide D IC50 NSCLC-N6 5.2 µg/mL.
petrosaspongiolide E IC50 NSCLC-N6 4.5 µg/mL.
petrosaspongiolide F IC50 NSCLC-N6 8.7 µg/mL.
petrosaspongiolide G Inactive against NSCLC-N6.
petrosaspongiolide H IC50 NSCLC-N6 8.1 µg/mL.
petrosaspongiolide I IC50 NSCLC-N6 6.8 µg/mL.
petrosaspongiolide J IC50 NSCLC-N6 6.3 µg/mL.
petrosaspongiolide K IC50 NSCLC-N6 1.3 µg/mL.
petrosaspongiolide L IC50 NSCLC-N6 5.7 µg/mL.
petrosaspongiolide M
anti-inflammatory
PLA2 inhibitors (10 µM) 71% bee venom, 11.5% N. naja venom, 12.3%
porcine pancreas and 68.6% human synovial.
[90]
petrosaspongiolide N PLA2 inhibitors (10 µM) 43.9% bee venom, 6.8% N. naja venom, 11.6%porcine pancreas and 44.0% human synovial.
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PLA2 inhibitors (10 µM) 37.9% bee venom, 3.0% N. naja venom, 0.0%
porcine pancreas and 60.9% human synovial.
Petrosaspongia nigra [90]petrosaspongiolide Q
PLA2 inhibitors (10 µM) 12.5% bee venom, 4.2% N. naja venom, 0.0%
porcine pancreas and 30.1% human synovial.




IC50 KB 1.5 µg/mL.
MIC (µg/mL) Sf 5, Sa 1, Ec 1, Pa 10
Phloeodictyon sp.
[91]
phloeodictine B IC50 KB 11.2 µg/mL.MIC (µg/mL) Sf > 15, Sa 3, Ec 30, Pa > 30
phloeodictine A1 IC50 KB 2.2 µg/mL.
2.6:1 mixture of phloeodictine A1 and A2. MIC (µg/mL) Sa 3, Ec 3, Pa




IC50 KB 3.5 µg/mL.
2.6:0.7:0.3 mixture of phloeodictine A3, A4 and A5.
MIC (µg/mL) Sa 30, Ec 30, Pa > 30, Cp > 30, Bf > 30 and Pas > 30
phloeodictine A4
phloeodictine A5
phloeodictine A6 IC50 KB 0.6 µg/mL.
1:1.4 mixture of phloeodictine A6 and A7.
MIC (µg/mL) Sa 1, Ec 3, Pa 30, Cp 1, Bf 3 and Pas 3phloeodictine A7
phloeodictine C1 IC50 KB 1.8 µg/mL. 1:1 mixture of phloeodictine C1 and C2. MIC




IC50 (nM) KB 1.5, HCT116 1.2, T47D 0.45, HBL100 1.7 and Chang
liver 2.4




IC50 (nM) KB 0.28, HCT116 0.22, T47D 0.18, HBL100 0.60, Chang
liver 0.24
G2/M cell cycle arrest in HL60 and KB cell lines (Ñ apoptosis).
echinosulfonic acid D alkaloid IC50 KB 2 µg/mL. [94]
psammaplysene C





IC50 (µg/mL) KB 0.10, P388 0.16, P388/Dox 0.01,
NSCLC-N6 0.07, HT29 0.04
Reidispongia coerulea
[83,96]
reidispongiolide B IC50 (µg/mL) KB 0.06, P388 0.06, P388/Dox 0.02,NSCLC-N6 0.05, HT29 0.04 [96]
reidispongiolide C
NCI screening: 60 human cell lines (9 cancer types: leukemia, lung,
colon, brain, melanoma, ovarian, renal, prostate and breast). Same
degree of cell line selectivity.
[83]
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IC50 KB 0.2 µg/mL.
Rhabdastrella globostellata
(formerly Aurora sp.) [97]
auroral 2
auroral 3 IC50 KB 8.0 µg/mL.
auroral 4
(+)-aeroplysinin-1







IC50 (µg/mL) KB 2.5, L1210 0.8
No in vivo activity against P388 leukemia cells.




IC50 (µg/mL) KB 2.5, L1210 2.0.
No in vivo activity against P388 leukemia cells.




IC50 (µg/mL) KB 2.0, L1210 0.2
No in vivo activity against P388 leukemia cells. [99]
xestoamine β-carboline alkaloid Inactive against KB and L1210 cell lines.
Footnote: Statistics: IC50 half maximal inhibitory concentration, Ki inhibition constant, CD50 median cytotoxic dose, ED50 median effective dose, SI selectivity index, EC50 median
effective concentration, IC90 inhibitory concentration 90%, MIC minimum inhibitory concentration. Cell lines: KB human nasopharyngeal epidermoid carcinoma, L1210 murine
lymphocytic leukemia, P388 murine leukemia, P388/Dox murine leukemia doxorubicin-resistant, NSCLC-N6, NSCLC-N6-L16: human non-small-cell bronchopulmonary carcinoma,
NSCLC-N6 C15 human non-small-cell bronchopulmonary carcinoma clone 15, NSCLC-N6 C92 human non-small-cell bronchopulmonary carcinoma clone 92, NSCLC-N6 C98 human
non-small-cell bronchopulmonary carcinoma clone 98, E39 human renal carcinoma, M96 human melanoma, Jurkat human T leukemia, HBL100, T47D: human breast epithelial, T24
human bladder carcinoma, MCF-7 human breast adenocarcinoma, MCF-7R human breast adenocarcinoma resistant, HCT116, HCT15, HT29: human colon adenocarcinoma, OVCAR8,
OV3: human ovary adenocarcinoma, PC3 human prostate adenocarcinoma, Vero monkey kidney, MRC5 fetal human lung, HL60 human promyeocytic leukemia, HL60R human
promyeocytic leukemia resistant, K562 human erythromyeloblastoid leukemia, PaCa human pancreas carcinoma, SF268 human glioblastoma, A549 human lung carcinoma, MDA231,
MDA435: human breast adenocarcinoma, HepG2 human hepatocarcinoma, EPC epithelioma papulosum cyprini, U266 human multiple myeloma, SKM1 human acute myeloid leukemia,
Kasumi human leukemia, THP-1 human monocytic leukemia. Proteins: GSK-3β glycogen synthase kinase-3β, SRIF somatotropin release inhibiting factor, VIP vasoactive intestinal
peptide, CDC25A protein phosphatase, CDK1 cyclin-dependent kinase 1, CDK2 cyclin-dependent kinase 2, CDK5 cyclin-dependent kinase 5, p25 protein, CK1 casein kinase 1, PLK-1
polo-like kinase 1, PLA2 phospholipase A2, NPY neuropeptide Y, TPK tyrosine protein kinase, NK3 tachykinin receptor 3, AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid, CGRP calcitonin gene-related peptide, NT neurotensin. Viruses: HIV-1 human immunodeficiency virus type 1; AZT azidothymidine, antiretroviral drug. Fungi: Ca Candida
albicans, Ct Candida tropicalis, Pc Phythothora citrophthora, Pci Phythothora citnnamomi, Pr Pythium rostatum, Pv Pythium vexans, Bc Botrytis cinerea, Po Pericularia oryzae, Fr Fusarium roseum,
Aa Alternaria alternata, Rs Rhizoctonia solani, Ph Pseudocercosporella herpotrichoides, Sn Septoria nodorum, Hg Helminthosporium gramineum, Un Ustilago nuda. Bacteria: Sa Staphylococcus
aureus, Ec Escherichia coli, Pf Plasmodium falciparum, CQ-sensitive Pf chloroquine-sensitive Plasmodium falciparum, CQ-resistant Pf chloroquine-resistant Plasmodium falciparum, Pf F32,
FcB1, PFB: Plasmodium falciparum chloroquine-susceptible F32, chloroquine-resistant FcB1, chloroquine-resistant PFB, Sf Streptococcus faecalis, Pa Pseudomonas aeruginosa, Cp Clostridium
perffingens, Bf Bacteroides fragilis, Pas Peptococcus assaccharolyricus. Others: NO nitric oxide, NCI National Cancer Institute, N. naja Naja naja, IP3 inositol-1,4,5-trisphosphate.
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5.1.2. Porifera Success Stories
New Caledonian sponges have revealed more exciting chemicals than any other studied taxon,
in terms of carbon skeleton, degree and patterns of unsaturation, halogenation, functional group
originality, presence of unusual heteroatoms etc. Some of these features are responsible for the rather
exceptional bioactivity profiles encountered. Some outstanding examples are described below:
Cymbastela Cantharella
Cymbastela cantharella (Family Axinellidae, Class Demospongiae, formerly Pseudaxinyssa
cantharella, Figure 5A) was collected on the outer south reef of New Caledonia at depths ranging
from 10 to 40 m (voucher #R1279, IRD Nouméa).
Chemical analyses led to the isolation of sterols that contain a 3β-hydroxymethyl-A-norcholestane
skeleton, a typical feature of the Axinellidae (1–3, Figure 5B) [100], along with alkaloids such as odiline
(4, Figure 5B), dibromocantharelline (5, Figure 5B) and dibromophakellin (6, Figure 5B) [53]. Studies
performed on the crude ethanol extracts of C. cantharella led to the isolation of girolline (7, Figure 5B). Its
absolute configuration has been established by X-ray diffraction [56] and total synthesis was achieved
few years later [53,57,58,63,100].
Girolline (7, Figure 5B) (or girodazole) has demonstrated potent antiproliferative activity in vitro
on several cell lines such as P388 murine leukemia and P388/dox, a sub-line resistant to doxorubicin, an
anthracycline, or KB naso-pharyngeal and T24 bladder carcinoma human cell lines. The half maximal
inhibitory concentration (IC50) values are 0.06 µM, 0.08 µM, 0.21 µM and 0.19 µM, respectively [55].
Subsequent in vivo assays have been performed on several grafted murine tumors used for preclinical
evaluation including P388 and L1210 leukemia, and solid tumors such as M5076 histiocytosarcoma
and MA/16C mammary adenocarcinoma cells [54,59,63]. Moreover, girodazole (7, Figure 5B) also has
antitumor activity in vivo on the P388/dox cell line. This compound may inhibit the termination step
of protein synthesis in vivo [60,61]. Although toxicological studies in mice and dogs do not show any
major toxic effects, girodazole (7, Figure 5B) clinical development was interrupted in 1991 in phase II
due to severe side effects, in particular cardiovascular toxicity [59].
Girolline (7, Figure 5B) has also shown promising results for the treatment of malaria.
This compound has demonstrated potent antiplasmodial activities against four Plasmodium falciparum
strains with IC50 values ranging from 77 to 215 nM, and may act synergistically with chloroquine
in vitro by affecting protein synthesis [62].
Other studies have led to the characterization of pyraxinine (8, Figure 5B), a novel nitrogenous
compound, along with previously identified allantoin (9, Figure 5B), homarine (10, Figure 5B) and
trigonelline nitrogen compounds (11, Figure 5B) [63], hymenialdisine (previously identified; 12,
Figure 5B) and new pyrrole-2-aminoimidazole alkaloids, which are dihydrohymenialdisine derivatives
(13, Figure 5B) [64]. Further investigations revealed that hymenialdisine (12, Figure 5B) is a powerful
inhibitor of cyclin-dependent kinases such as CDK1/cyclin B, CDK2/cyclin A and CDK2/cyclin E
(IC50 values of 22 nM, 70 nM, and 40 nM, respectively), CDK5/p25 (IC50 of 28 nM), as well as against
glycogen synthase kinase-3β (GSK-3β) with an IC50 of 10 nM and casein kinase 1 (CK1) with an IC50
of 35 nM [44].












































Figure  5.  (A)  Cymbastela  cantharella.  ©  IRD;  (B)  Structure  of 
hydroxymethyl‐3β‐methyl‐24S‐nor‐A‐cholest‐5α‐ene‐22‐Z  (1), 
hydroxymethyl‐3β‐methyl‐24R‐nor‐A‐cholest‐5α‐ene‐22‐Z  (2), 
hydroxymethyl‐3β‐ethyl‐24ξ‐methyl‐26ξ‐nor‐A‐cholest‐5α‐ene‐22‐E  (3),  odiline  (4), 
Figure 5. (A) Cymbastela cantharella. © IRD; (B) Structure of hydroxymethyl-3β-methyl-24S-
nor-A-cholest-5α-ene-22-Z (1), hydroxymethyl-3β-methyl-24R-nor-A-cholest-5α-ene-22-Z (2),
hydroxymethyl-3β-ethyl-24ξ-methyl-26ξ-nor-A-cholest-5α-ene-22-E (3), odiline (4), dibromocantharelline
(5), dibromophakellin (6), girolline (7), pyraxinine (8), allantoin (9), homarine (10), trigonelline (11),
hymenialdisine (12) and dihydrohymenialdisine (13).
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Echinochalina Bargibanti
The demosponge Echinochalina bargibanti (voucher #R1858, IRD Nouméa, Figure 6A) was collected
along the northeastern coast of Grande Terre between 18 and 25 m depth during the SMIB program.
A bioassay-guided fractionation of its organic extracts led to the isolation of arsenicin A (14, Figure 6B),
the first polyarsenic compound ever found in nature.
Arsenicin A (14, Figure 6B) demonstrates potent bactericidal and fungicidal activities against
human pathogenic strains such as Staphylococcus aureus, Escherichia coli and Candida albicans with
inhibition circles of 24, 28 and 26 mm respectively at 10 µg per disk. In contrast, gentamicin, which is
the reference antibiotic, induces inhibition circles of 22, 30 and 22 mm [68]. Arsenicin A (14, Figure 6B)
has been synthesized and its crystal structure determined [101]. An improvement in this synthesis has
led to (˘)-arsenicin A which shows potent antiproliferative activity on acute promyelocytic leukemia
cell lines. This compound is more potent than arsenic trioxide (Trisenox) which is used for treating
acute promyelocytic leukemia. (˘)-Arsenicin A has also demonstrated antiproliferative activity against















has  led  to  (±)‐arsenicin A which  shows  potent  antiproliferative  activity  on  acute  promyelocytic 
leukemia cell lines. This compound is more potent than arsenic trioxide (Trisenox) which is used for 












Dendrilla  sp.  (voucher  #R171,  IRD  Nouméa)  is  a  common  shallow‐water  (lagoon,  at 






7)  include antitumor, anti‐inflammatory and antimicrobial  [103] properties with potential  interest 
for shrimp aquaculture for treating Vibrio pathogens [104]. 
Chemically,  dendrillid  sponges  are  known  to  contain  lamellarins  A–B  (15–18,  Figure  8), 
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Dendrilla sp.
Dendrilla sp. (voucher #R171, IRD Nouméa) is a common shallow-water (lagoon, at approximately
20 m depth) dendroceratid sponge belonging to the Demospongiae. It features an unusual “scouring
pad” appearance with its spongin fibers protruding from an elastic tissue mass that can vary in color
from dark green to reddish.
R171 is cytotoxic in brine shrimp larvae bioassays [103], and its crude aqueous extract is toxic
to the mosquito fish Gambusia affinis, causing erratic swimming patterns followed by 100% mortality
within 12 h [29]. Reported biological activities of the crude organic extracts of Dendrilla nigra (Figure 7)
include antitumor, anti-inflammatory and antimicrobial [103] properties with potential interest for
shrimp aquaculture for treating Vibrio pathogens [104].
Chemically, dendrillid sponges are known to contain lamellarins A–B (15–18, Figure 8),
aromatic alkaloids of probable symbiotic origin. These pyrrole derivatives are antitumoral (HIF-1
inhibitors) [105]. Dendrilla cactos contains cyclic bastadins, which are bromotyrosine-derived
peptides endowed with Gram+ antibacterial and anti-inflammatory properties; in addition they
inhibit topoisomerase II, dehydrofolate reductase and the endothelin A receptor [106]. Cold-water
Dendrilla membranosa contains membranolides used as natural antifeedants and other microbe-derived
bioactive compounds [107]. The suspicion that indwelling bacteria may be responsible for much of the
reported bioactivities in sponges in the Dendrilla genus has prompted the taxonomic characterization
of culturable strains in Dendrilla nigra [108].






Figure  8. Structure of neolamellarin A  (15), 7‐hydroxylamellarin A  (16), neolamellarin B  (17) and   
5‐hydroxylamellarin B (18). 
Another  interest  in Dendrilla R171 stems from bioassays as serine protease  inhibitors (§ 4.1.4) 
with  remarkable anti‐trypsin and anti‐elastase activities  in preliminary benchtop assays on crude 




amino  acid,  but  the  structure was  never  published.  This was  long  before  aeruginosins,  peptide 
anti‐serine  proteases  first  isolated  from  cyanobacteria  in  1994. A whole  family  of more  than  20 





(or at  least unpublished)  to date. The  fact  that another  tested Dendrilla  (voucher  #1225) does not 
display  any  inhibitory  activity  suggests  that  microbial  symbionts—possibly  cyanobacteria—are 
involved in the reported R171 activities. 
Niphates sp. 
A  new C47  polyoxygenated  acetylenic  acid,  nepheliosyne  B  (20,  Figure  9B),  along with  the 
previously described nepheliosyne A (19, Figure 9B), have been isolated from Niphates sp. (Figure 9A), 
collected  in  2008  in  a  southwest  lagoon  at  22 m depth  (voucher  #MHNM  1646, Natural History 










Figure  8. Structure of neola ellarin A  (15), 7‐hydroxyla ellarin A  (16), neola ellarin B  (17) and   
5‐hydroxyla ellarin B (18). 
nother  interest  in  endrilla R171 ste s fro  bioassays as serine protease  inhibitors (§ 4.1.4) 
ith  re arkable anti‐trypsin and anti‐elastase activities  in preli inary benchtop assays on crude 
extracts.  ith  up  to  100   inhibition  on  both  bovine  trypsin  and  porcine  elastase  activities,  this 
sponge displays the  ost potent anti‐serpin activity of the 133 invertebrate species tested in total. In 
1988, collaborators in  ontpellier isolated the active co pound (a peptide) fro  the  ater‐ethanol 
extract, bioguided by an anti‐elastase assay (porcine and hu an) and they sequenced a 43‐residue 
a ino  acid,  but  the  structure  as  never  published.  This  as  long  before  aeruginosins,  peptide 
anti‐serine  proteases  first  isolated  fro   cyanobacteria  in  1994.    hole  fa ily  of  ore  than  20 




Thus, the identity of the trypsin and elastase inhibitor(s) fro   endrilla R171 re ains unkno n 
(or at  least unpublished)  to date. The  fact  that another  tested  endrilla  (voucher  #1225) does not 
display  any  inhibitory  activity  suggests  that  icrobial  sy bionts possibly  cyanobacteria are 
involved in the reported R171 activities. 
iphates sp. 
  ne  C47  polyoxygenated  acetylenic  acid,  nepheliosyne  B  (20,  Figure  9B),  along  ith  the 
previously described nepheliosyne   (19, Figure 9B), have been isolated fro   iphates sp. (Figure 9 ), 
collected  in  2008  in  a  south est  lagoon  at  22   depth  (voucher  #   1646,  atural  istory 
useu   of  arseille,  ainland  France).  Both  nepheliosyne    and  B  have  sho n  cytotoxicity 
against K562 chronic  yelogenous leuke ia,  266  yelo a, SK 1  yelodysplastic syndro  and 
Kasu i acute  yeloid leuke ia hu an cell lines  ith IC50 values ranging fro  150 to 200 μ  [86]. 
Several polyhydroxylated acetylenic  etabolites of  arine sponges  ith a diacetylenic carbinol and 
Figure 8. Structure of neolamellarin A (15), 7-hydroxylamellarin A (16), neolamellarin B (17) and
5-hydroxylamellarin B (18).
Another interest in Dendrilla R171 stems from bioassays as serine protease inhibitors (§ 4.1.4) with
remarkable anti-trypsin and anti-elastase activities in preliminary benchtop assays on crude extracts.
With up to 100% inhibition on both bovine trypsin and porcine elastase activities, this sponge displays
the most potent anti-serpin activity of the 133 invertebrate species tested in total. In 1988, collaborators
in Montpellier isolated the active compound (a peptide) from the water-ethanol extract, bioguided
by an anti-elastase assay (porcine and human) and they sequenced a 43-residue amino acid, but the
structure was never published. This was long before aeruginosins, peptide anti-serine proteases first
isolated from cyanobacteria in 1994. A whole family of more than 20 aeruginosins has been described
since then, some from sponges of the genus Dysidea [109]. The presence of such compounds may
explain the anti-trypsin activity if aeruginosins are also present in Dendrilla R171 (which has not been
verified), but anti-elastase activity has never been associated with these molecules.
Thus, the identity of the trypsin and elastase inhibitor(s) from Dendrilla R171 remains unknown
(or at least unpublished) to date. The fact that another tested Dendrilla (voucher #1225) does not display
any inhibitory activity suggests that microbial symbionts—possibly cyanobacteria—are involved in
the reported R171 activities.
Niphat s sp.
A new C47 polyoxygenated acetylenic acid, nepheliosyne B (20, Figure 9B), along with the
previously described nepheliosyne A (19, Figure 9B), have been isolated from Niphates sp. (Figure 9A),
collected in 2008 in a southw st lagoon at 22 m d th (voucher #MHNM 1646, Natural History
Museum of Ma seille, mainland France). Both nepheliosyne A and B have shown cytotoxicity against
K562 chro ic myelogenous leukemia, U266 myeloma, SKM1 my lodysplastic syndrom and Ka umi
ac t myeloid leukemia huma cell li es with IC50 values ra ging from 150 to 200 µM [86]. Several
polyhydroxylated acetylenic metabolites of marine sponges with a diacety enic carbinol a a α-y e
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carboxylic group have been reported: nepheliosyne A (19, Figure 9B) from Xestospongia sp., petrosolic
acid (21, Figure 9B) from Petrosia sp., osirisynes (22–27, Figure 9B) and haliclonyne (28, Figure 9B) from
Haliclona sp., and fulvynes A–I (29–37, Figure 9B) from Haliclona fulva. Nepheliosyne B (20, Figure 9B)
is, along with nepheliosyne A (19, Figure 9B) and petrosolic acid (21, Figure 9B), the third example of a
linear acetylene with diacetylenic carbinol, α-hydroxyketone, and α-yne carboxylic groups. All these
data suggest that, from a chemotaxonomic point of view, polyhydroxylated acetylenic metabolites
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(40,  Figure  10), D  (41,  Figure  10)  and  E  (42,  Figure  10).  These  porphyrins may  be  used  as  new 
photosensitizers in phototherapy, particularly by generating singlet oxygen toxic to cancer cells [51]. 
Figure 9. (A) Niphates sp. Photo: Philippe Amade (INSERM); (B) Structure of nepheliosyne A
(19), nepheliosyne B (20), petrosolic acid (21), osirisynes A–F (22–27), haliclonyne (28) and fulvynes
A–I (29–37).
Corallistes sp.
is eep-sea sponge was collected by beam trawl at a depth of 350 m in the Coral Sea. The crude
dichloromethanol extract shows cytotoxic activities against the KB naso-p aryngeal carcinoma cell
line with an IC50 of 10 µg/mL. Subsequent chemical analyses led to the isolation f a free porphyrin
called corallistin A (38, Figure 10) [50]. Its total synthesis followed a few years later [110].
Further studies conducted on Corallistes sp. led to the isolation of corallistins B (39, Figure 10),
C (40, Figure 10), D (41, Figure 10) and E (42, Figure 10). These porphyrins may be used as new
photosensitizers in phototherapy, p rticularly by en rating singlet xygen toxic to cancer cells [51].
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harbor  cyanobacterial  photosymbionts,  e.g.,  the  photosynthetic  genus  Prochloron which  lives  in 
symbiosis with its host [111]. 
This class has a special “defense” feature: they can concentrate some toxic elements including 
heavy metals  (notably vanadium), hydrocarbons  and  elementary  sulfur, which may be  found  in 




Figure 10. Structure of corallistin methyl ester A (38), B (39), C (40), D (41), and E (42).
5.2. Ascidians
5.2.1. General Comments
Ascidians are invertebrate filter feeders that belong to phylum Chordata. They represent the most
evolved invertebrates with a heart and a respiratory system. Living in both solitary and colonial sessile
modes, ascidians can be found in all the world’s seas and at all depths. The external tunic of sea-squirts
(tunicates) is made of tunicin, a cellulosic substance that is extremely rare in the animal kingdom [19].
Didemnids are soft-bodied, bag-like organisms. Like sponges, didemnids can harbor cyanobacterial
photosymbionts, e.g., the photosynthetic genus Prochloron which lives in symbiosis with its host [111].
This class has a special “defense” feature: they can concentrate some toxic elements including
heavy metals (notably vanadium), hydrocarbons and elementary sulfur, which may be found in
Polycarpa aurata, or even sulfuric acid concentrated inside tiny vesicles of the outer tunic. Studies have
also revealed high amounts of nitrogenous compounds (cyclic peptides and alkaloids) with powerful
biological activities [112] (Table 3). As of 2007, 290 tunicates had been identified in New Caledonian
waters [5].
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Table 3. Natural products isolated from New Caledonian ascidians and their bioactivity.
Natural Product Chemical Class Biological Activity Species Reference
eudistalbin A
β-carboline alkaloid antiproliferative
ED50 KB 3.2 µg/mL.
Eudistoma album [113]eudistalbin B Inactive on KB cell line.
eudistomin E ED50 KB < 5 ng/mL.
(´)-woodinine
alkaloid antibacterial
Sa 16 mm/100 µg/disk and 18 mm/200 µg/disk.
Ec 8/100 µg/disk and 11 mm/200 µg/ disk. Eudistoma fragum [114]
5-bromo-N,N-
dimethylamino-ethyltryptamine
Sa 12 mm/100 µg/disk and 17 mm/200 µg/disk.





IC50 (nM) KB 45, P388 20 and normal human endothelial cells 22
IC50 NSCLCN6-L16 0.49 µM at 67 h.




antibacterial Inactive agaisnt Ec, Kp, Mm, Pm, Pv, Pa, Sm, Sa and Streptococcusgroup D (500 µg/mL).
mechanism of action G1 cell cycle arrest in NSCLCN6-L16 cells; polyploidy-inaptitudefor cytokinesis.
Na+ channels inhibitor At rest and in the inactivated state, occupied a site which was notlocated on the inactivation gate.
Ca2+ sensitivity
immunomodulator
Binding to contractile proteins for which it competes with Ca2+.




IC50 (µg/mL) KB 2.10, P388 0.20, P388/Dox 1.16, B16 1.20, HT29 0.71,
NSCLC-N6 0.32. Significant decreases of S phase in NSCLC-N6 cells.
[117]
bistramide C IC50 (µg/mL) KB 0.65, P388 0.02, P388/Dox 0.05, B16 0.06, HT29 0.50,NSCLC-N6 0.05. Significant decreases of S phase in NSCLC-N6 cells.
bistramide D
IC50 (µg/mL) KB 10.00, P388 0.36, P388/Dox 5.82, B16 0.10, HT29
2.76, NSCLC-N6 3.43; In vivo (IV and IP) antitumor activity in nude
mice engrafted SC with NSCLC-N6, T/C 53% at day 30. Significant




IC50 (µg/mL) KB > 10.00, P388 0.57, P388/Dox > 10.00, B16 1.90,
HT29 5.60, NSCLC-N6 3.23; In vivo (IV and IP) antitumor activity in
nude mice engrafted SC with NSCLC-N6, T/C 49% at day 30. G1 cell







IC50 (ng/mL) KB 14, P388 1, P388/Dox 300 and NSCLC-N6 9; G1 cell
cycle arrest in NSCLC-N6 cells (irreversible, total, dose-and
time-dependent). Lissoclinum voeltzkowi
[121,122]
chlorolissoclimide antiproliferativemechanism of action
IC50 (ng/mL) KB 52, P388 1.7, P388/Dox 200 and NSCLC-N6 10; G1
cell cycle arrest in NSCLC-N6 cells. [121–123]
arborescidine D indole alkaloid antiproliferative IC50 KB 3 µg/mL. Pseudodistoma arborescens [124]
Footnote: Statistics: ED50 median effective dose, IC50 half maximal inhibitory concentration, T/C tumor growth inhibition ratio. Cell lines: KB human nasopharyngeal epidermoid
carcinoma, P388 murine leukemia, P388/Dox murine leukemia doxorubicin-resistant, NSCLCN6-L16, NSCLC-N6: human non-small-cell bronchopulmonary carcinoma, B16 murine
melanoma, HT29 human colon adenocarcinoma. Bacteria: Sa Staphylococcus aureus, Ec Escherichia coli, Kp Klehsiella pneumoniae, Mm Morganella morganii, Pm Proteus mirabilis, Pv Proteus
vulgaris, Pa Pseudomonas aeruginosa, Sm Serratia mareescens. Ions: Na+ sodium, Ca2+ calcium. Others: IV intravenous, IP intraperitoneal, SC subcutaneous.
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5.2.2. Lissoclinum bistratum
The didemnid Lissoclinum bistratum (voucher # UA264, IRD Nouméa, Figure 11A) was
collected near the Ua islet in the southwest lagoon. Chemical studies followed when two cases
of human intoxication were observed during manipulation of the lyophilized powder. The crude
dichloromethanol extract of L. bistratum demonstrates acute toxicity on rats, mice and rabbits. Moreover,
it has revealed cytotoxic activities with IC50 values of 45 nM, 20 nM and 22 nM on KB, P388 and normal
human endothelial cells, respectively [115].
Separation and purification led to the isolation of a tetrahydropyran derivative called bistramide
A (43, Figure 11B) (or bistratene). Its partial structure has been characterized using two dimensional
NMR techniques [125].
Bistramide A (43, Figure 11B) appears to block the division of NSCLC-N6 (L16) cells at the
G1 phase after a 24 h incubation period at a concentration of 1.42 µM. The IC50 value is 0.49 µM.
Bistramide A (43, Figure 11B) may also induce polyploidy, causing unsuccessful cytokinesis [116].
It has revealed immunomodulator activities (suppressor/stimulator) on the proliferation of T and B
cells [120]. Moreover, demonstrated using the voltage-clamp technique, bistramide A (43, Figure 11B)
has proven to be responsible for a resting block by inhibiting sodium channels [118] and can bind to
contractile proteins in competition with calcium in frog skeletal muscle fibers [119].
Later investigations performed on L. bistratum led to the isolation of new tetrahydropyran
derivatives called bistramides B (44, Figure 11B), C (45, Figure 11B), D (46, Figure 11B) and K (47,
Figure 11B). Bistramides A (43, Figure 11B), B (44, Figure 11B) and C (45, Figure 11B) show potent
cytotoxic activities with IC50 values of less than 1 µg/mL on several cancer cell lines including KB,
P388, P388 doxorubicin-resistant, B16, HT29, NSCLC-N6, MRC5CV1 fibroblasts and T24 bladder
carcinoma cells. Bistramide K (47, Figure 11B), which is the least toxic compound, induces a complete
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This  phylum  is  divided  into  two  subclasses,  Octocorallia,  which  includes  alcyonarians, 
gorgonians and pennatularians, and Hexacorallia, which includes scleratinarians. The chemical and 
biological properties of Cnidaria collected in New Caledonia are reported in Table 4. 
Figure 11. (A) Lissoclinum bistratum, © IRD; (B) Structure of bistramide A (43), B (44), C (45), D (46),
and K (47).
5.3. Cnidaria
This phylum is divided into two subclasses, Octocorallia, which includes alcyonarians, gorgonians
and pennatularians, and Hexacorallia, which includes scleratinarians. The chemical and biological
properties of Cnidaria collected in New Caledonia are reported in Table 4.
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Table 4. Natural products isolated from New Caledonian Cnidaria and their bioactivity.
Natural Product Chemical Class Biological Activity Species Reference
7-epi-11,19-desoxyhavannahine xenicane diterpene anti-fouling
Ceramium codii RGR after 2 days: 4% of
control at 50 ppm, 21% at 25 ppm, 42% at
12.5 ppm.
Xenia garciae [33]
iela melst protein elastase inhibitor Inhibitor of amidolysis of Suc(Ala)3p-NA byporcine pancreatic elastase (Ki 1.5 nM).
Melithea cf. stormii [37]
villogorgin A caffeine-xanthine typealkaloid anti-inflammatory
Acetylcholine antagonist. Anti-aggregatory
(thrombin, A23187). Villogorgia rubra [127]
lituarine A
polyethermacrolide antiproliferative
IC50 KB 3.7–5 ng/mL.
Lituaria australasiae [128]lituarine B IC50 KB 1–2 ng/mL.
lituarine C IC50 KB 5–6 ng/mL.
pteroidin
briarane diterpene ichtyotoxic
LD100 50 µg/mL, t = 90 min (fish of the
genus Mugil).
Pteroides laboutei [129]
O-deacetyl-12-O-benzoyl-12-pteroidin LD100 50 µg/mL, t = 150 min (fish of thegenus Mugil).
Statistics: RGR Relative Growth Rate, Ki inhibition constant, IC50 half maximal inhibitory concentration, LD100 lethal dose 100%. Cell line: KB human nasopharyngeal epidermoid
carcinoma. Other: A23187 calcium ionophore.
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5.3.1. Alcyonarians
General Comments
Alcyonarians also called “soft corals” because they lack a calcium carbonate skeleton.
This carbonate skeleton is replaced in most species by aragonitic sclerites, which are of major taxonomic
importance for identification. They are benthic, sessile, colonial organisms often composed of many
individual polyps stemming from a common sterile trunk, which is attached to the substratum by a
glycoprotein “glue”. The main families are the Alcyoniidae, Nephtheidae and Xeniidae.
Alcyonarians often possess endodermal zooxanthellae which provide them with oxygen and
photosynthates due to their photosynthetic activity. A total of 173 species have been reported in New
Caledonian waters [5].
“Cocktails” of toxic secondary metabolites, especially diterpenes, occur in their tissues, and
serve anti-predator (toxic and emetic effects) [130] and anti-competitor defense functions (contact
necrosis and allelopathic growth inhibition [131], but also as anti-fouling substances and as egg
protectants [132]).
Octocorals, which includes alcyonarians, gorgonians and pennatularians, are chemically
characterized by terpenes, oxylipins such as prostaglandins and prostanoids, sterols and some aromatic
derivatives [133]. These compounds have promising pharmacological value (Table 4).
Xenia Garciae
The “soft coral” Xenia garciae (voucher #3526, Northern Territory Museum, Darwin, Australia)
was collected in shallow-water fringing reefs at a depth less than five meters. Chemical analyses
isolated an original xenicane diterpene (48, Figure 12) that inhibits the growth of Ceramium codii,
which is a common benthic Rhodophyta contributing to the process known as “fouling” [33]. Around
the xenicane skeleton, as around the cembrane skeleton of alcyonids, are found dozens of bioactive
diterpenes. The xenicane diterpenes, also found in some brown algae (Dictyotales), are particularly
interesting as synthetic templates for the design of antitumor drugs [134].
ar.  rugs 2016, 14, x 
 
5.3.1.  lcyo aria s 
   
i s  ls   ll   ft  r ls”  ca se  t ey  lac     l i   r o ate  skeleton.   
  carbonate  sk leton  is  replaced  in most  species  by  aragonitic  scler tes, which  are  of major 
taxonomic importance for identification. They are b nthic, sessile, c lonial organisms  ften composed of 
many individual polyps stemming from a common s erile trunk, which is attached to the substratum 
by a glycoprotein “glue”. The main families are the Alcyoniidae, Nep theidae and Xeniidae. 
i s  ft     l  t ellae  ic   r i e    i      
  e  to  their photosynthetic act vity. A  total of 173  species hav  been  eported  in 
New Caledonian waters [5]. 
t il         ,  i ll   s,  r  i        
  ‐ t r  ic      eff   [   and  anti‐co t   f   f   (  
r sis    l athic  ro th  i ibition  [131],  but  lso    ‐ ling  stances  and     
t ts [132]). 
l ,  ic   l   i ,  r i s    i ,     
  by  terpenes,  oxylipins  such  as  prostaglandins  and  prostanoids,  sterols  and  some 
arom c derivatives [133]. These compounds have promising pharmaco ogical value (Table 4). 
enia  arciae 
The “soft coral”  enia garciae (voucher #3526,  orthern Territory  useu ,  ar in,  ustralia) 
as collected  in shallo ‐ ater  fringing  reefs at a depth  less  than  five  eters.  he ical analyses 
isolated an original xenicane diterpene  (48, Figure 12)  that  inhibits  the gro th of Cera iu  codii, 
hich  is  a  co mon  benthic  Rhodophyta  contributing  to  the  process  known  as  “fouling”  [33]. 
Around the xenicane skeleton, as around the cembrane skeleton of alcyonids, are found dozens of 



















Figure 12. Structure of xenicane (48).
5.3.2. Gorgonians
General Co ents
Also kno n as sea hips or sea fans, gorgonians are “ani al-flo ers” that are supported either
by a calcareous skeleton (suborder Scleraxonia) or by a flexible horny skeleton (suborder olaxonia)
ade of a fibrous protein, gorgonin. Exclusively marine, these sessile invertebrates can live as solitary
animals or in colonies. They are found in many places in all oceans and can occur in different growth
forms such as bushes, whip-like branches and sometimes as blunt lobes or even flat crusts [18]. As of
2007, 93 species of gorgonians have been described in New Caledonian waters [5].
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Melithea cf. Stormii
The sea fan Melithea cf. stormii (Figure 13A) is a large scleraxonian gorgonian commonly found on
outer reef slopes. The voucher sample and the biological material used for sequencing and bioassays
were taken from only one medium-sized specimen (voucher #HG163, IRD Nouméa) collected in Uitoe
Pass, Southern Province at 20 m depth. Below, we summarize the main highlights of this specimen
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of  iela melst  (49). Half  cysteine  residues  are noted  in  red,  and  correspond  to half‐cysteines of  the 
non‐classical Kazal‐type inhibitor. The blue pair indicates P1‐P1’ residues around the putative active 
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The  presence  of  such  a  strong  anti‐elastase  substance  in  gorgonian  cortical  tissues may  hinder 
various  necrotic  processes  caused  by  epibiotic  fouling  or  extracoelenteric  digestion  by  other 
coelenterates [37]. 
Villogorgia Rubra 
Studies performed on  the gorgonian Villogorgia rubra, collected near  the Chesterfield  Islands, 
led to the characterization of two new alkaloids called villogorgin A (50, Figure 14) and B (51, Figure 
Figure 13. (A) Melithea cf. stormii. Photo: Philippe Plailly (CNRS); (B) N-terminal amino acid sequence
of iela melst (49). Half cysteine residues are noted in red, and correspond to half-cysteines of the
non-classical Kazal-type inhibitor. The blue pair indicates P1-P1’ residues around the putative active
site. One-letter codes for amino acids: A, alanine; C, cysteine; D, aspartate; E, glutamate; G, glycine; I,
isoleucine; K, lysine; L, leucine; M, methionine; P, proline; S, serine; T, threonine; V, valine; X, unknown;
Y, tyrosine.
From HG163, a 95% pure novel peptide elastase inhibitor was isolated using SEC and
reversed-phase chromatography. This peptide of 39 residues in length was hereafter referenced as iela
melst (49, Figure 13B) according to nomenclature. The amino acid sequence of the first 20 N-terminal
residues of iela melst (49, Figure 13B) is homologous to that of iela anesu from the sea anemone Anemonia
sulcata, a non-typical Kazal-type elastase inhibitor [135]. The Cha procedure [136] was used to monitor
the inhibition kinetics of the amidolysis of the synthetic substrate [Suc(Ala)3pNA] by porcine pancreatic
elastase (PPE) at different concentrations using iela melst (49, Figure 13B). This inhibitor works as a
slow, tight-binding inhibitor of PPE. The equilibrium dissociation constant Ki (1.5 nM) of the complex
is quite similar to that of the PPE-elafin complex, the latter being an antileuko-proteinase isolated from
patients with psoriasis. The anti-elastase activity of iela melst (49, Figure 13B) is very comparable to
those of most natural or synthetic PPE inhibitors. The presence of such a strong anti-elastase substance
in gorgonian cortical tissues may hinder various necrotic processes caused by epibiotic fouling or
extracoelenteric digestion by other coelenterates [37].
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Villogorgia Rubra
Studies performed on the gorgonian Villogorgia rubra, collected near the Chesterfield Islands, led to
the characterization of two new alkaloids called villogorgin A (50, Figure 14) and B (51, Figure 14), along
with known compounds: caffeine (52, Figure 14), tryptamine (53, Figure 14), Nb-methyltryptamine (54,
Figure 14) and 1,2,3,4-tetrahydro-β-carboline (55, Figure 14).
Villogorgin A (50, Figure 14) inhibits (i) the contraction of the guinea pig ileum induced by
acetylcholine; (ii) the aggregation of human platelets induced by thrombin and calcium ionophore
A23187; this inhibition may be due to modulation of calcium/calmodulin-dependent enzymes.
Villogorgin A (50, Figure 14) and B (51, Figure 14) are structurally related to the marine tunicate
β-carboline alkaloid eudistomidin-A (56, Figure 14), a strong calmodulin antagonist [127].
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Figure 14. Structure of villogorgin A (50), villogorgin B (51), caffeine (52), trypta ine (53),
Nb-methyltryptamine (54), 1,2,3,4-tetrahydro-β-carboline (55) and eudistomidin-A (56).
5.3.3. Pennatul rians
General Comments
Sea p ns (sea f thers)—also called pennatularians—are a specialized and mor l i ll
distinct group of octocorallian cnidarians.
Pennatularians are made of a thin tissue called the coenenchyme. These sessile ani als live in
colonies that are built from a single large primary polyp, the oozoid. They have been encountered in
all oceans down to 6100 m depth [137].
Lituaria Australasiae
Lituaria australasiae was collected at night, inside St. Vincent Bay (west coast, Southern Province).
From this octocoral, a novel class of macrocyclic lactones has been identified: lituarines A (57,
Figure 15), B (58, Figure 15) and C (59, Figure 15). Lituarines have demonstrated antifungal activities
on Fusarium oxysporum, Helminthosporium turscicum, Penicillium italicum and Phytophtora parasitica,
as well as cytotoxic activities on KB cells with IC50 values of 3.7–5.0 ng/mL for lituarine A (57,
Figure 15), 1–2 ng/mL for lituarine B (58, Figure 15) and ranging from 5–6 ng/mL for lituarine C (59,
Figure 15) [128].
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Figure 15. Structure of lituarine A (57), lituarine B (58) and lituarine C (59).
5.3.4. Scleractinians
Scleractinians are also called “stony corals” or “hard corals”. Scleractinian colonies act as biological
photosystems during sunlit hours and feed on plankton at night. Closely related to sea anemones, they
are also armed with cnidocytes that can be used for predation as well as for territorial defense [138].
“Stony corals” have a large range of colonial growth forms, from crustose to massive, but mostly
branching, corymbose, tabular or lamellate, with a few solitary and free-living forms, e.g., mushroom
corals [14]. All corals originate from a minute swimming planula that settles and metamorphoses into
a single solitary polyp, which itself undergoes successive budding to form a colony that encases itself
in an aragonitic (calcium/magnesium carbonate) shell. Growth rates can vary from a few centimeters
per year for fast growing branching acroporids that are shorter-lived and rarely very large, to a few
millimeters per year at most for large poritid corals that can grow up to 10 m in diameter and live for
many centuries.
Shallow-water corals contain Symbiodinium (symbiotic unicellular microalgae known as
zooxanthellae) within their endodermal cells. These microalgae give the coral its color, which thus can
vary in hue depending on the symbiont species. Scleractinians are usually photosymbiotes.
As of 2007, 310 species of scleractinians have been reported in New Caledonian waters [5].
Furthermore, the anthozoan Hexacorallia class may produce toxins (e.g., palytoxin) and other
secondary metabolites such as venoms, similar to those of sea anemones, or photoprotection pigments
(e.g., mycosporins, zoanthoxanthins) [139].
5.4. Echinoderms
5.4.1. General Comments
Phylum Echinodermata is divided into two subphyla, the Pelmatozoa including the class of
Crinoidea (crinoids, sea lilies an feather stars), and the Eleutherozoa which comprises Asteroidea
(starfish, sea stars), Echinoidea (sea urc ins), Holothuroidea (sea cucumbers) and Ophiuroidea (brittle
stars) [17].
Echinoderms are exclusively marine invertebrates that have an endoskeleton consisting of
magnesium calcite. In all, 257 species of echi oderms have been reported in New Caledonian waters
as of 2007 [5].
The therapeutic potential of these marine organisms is outlined in Table 5. Secondary metabolites
produced by Crinoidea are sulfated anthraquinonic pigments, whereas Eleutherozoa produce quinonic
igments, naphthoquinones or sulfated saponins (e.g., asterosaponins, holothurins) [140].
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Table 5. Natural products isolated from New Caledonian Echinodermata and their bioactivity.




DENV RF50% 1 µg/mL.




IC50 HIV-1 0.11 µg/mL. DENV inactive. Celerina heffernani
[142,143]
celeromycalin IC50 HIV-1 0.32 µg/mL. DENV inactive.
fromiamycalin IC50 HIV-1 0.11 µg/mL. Fromia monolis
crambescidin 800 IC50 HIV-1 0.11 µg/mL. DENV inactive.
(25S)-5α-cholestane-3β,4β,6β,
7α,8,15α,16β,26-octol sterol antifungal Active at 5 µg against Clodosporium cucumerinum. Rosaster sp. [144]
Footnote: Viruses: DENV dengue virus, HIV-1 human immunodeficiency virus type 1. Statistics: RF50% reduction factor 50%, IC50 half maximal inhibitory concentration.
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5.4.2. Actinopyga Flammea
The sea cucumber Actinopyga flammea (voucher #EH 025, IRD Nouméa) was collected at depths
ranging from 35 to 50 m on the outer reef slope on the New Caledonian west coast. Highly ichthyotoxic,
this species is used by fishermen in the Philippines to kill fish in coral holes. A specimen similar to that
shown in Figure 16A reportedly caused the death of all fish overnight after a caretaker accidentally
placed it in a fish tank at the Aquarium of Nouméa.
Chemical studies led to the purification and characterization of triterpenoid saponins
comprising the novel 24(S)-hydroxy-25-dehydro-echinoside A (60, Figure 16B), 22
ξ-hydroxy-24-dehydro-echinoside A (61, Figure 16B), 22 ξ-acetoxy-echinoside A (62, Figure 16B)
and 25-hydroxy-dehydroechinoside A (63, Figure 16B) which were minor compounds. A new
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(60),  22‐hydroxy‐24‐dehydro‐echinoside  A  (61),  22‐acetoxy‐echinoside  A  (62), 
25‐hydroxy‐dehydroechinoside A (63) and 16‐keto‐holothurinogenin (64). 
Figure 16. (A) Actinopyga flammea. © IRD; (B) Structure of 24(S)-hydroxy-25-dehydro-echinoside
A (60), 22-hydroxy-24-dehydro-echinoside A (61), 22-acetoxy-echinoside A (62), 25-hydroxy-
dehydroechinoside A (63) and 16-keto-holothurinogenin (64).
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5.4.3. Gymnochrinus Richeri
The “living fossil” Gymnochrinus richeri (voucher MNHN, Paris, mainland France, Figure 17A)
was collected in 1987 at a depth of 520 m on Stylaster Bank, Norfolk Ridge. Chemical studies isolated
gymnochromes A–D (65–68, Figure 17B), isogymnochrome D (69, Figure 17B), which constitute a new
group of brominated phenanthroperylenequinones with an hypericin core [141], and also of some
sterols such as cholest-4-en-3-one (70, Figure 17B) and cholesta-1,4-dien-3-one (71, Figure 17B) [146].
Gymnochromes B (66, Figure 17B), D (68, Figure 17B) and isogymnochrome D (69, Figure 17B)
possess antiviral activities in vitro against the human immunodeficiency virus (A. Bousseau,
unpublished results) and the dengue virus with a 50% viral titer reduction factor (RF50%) of less
than 1 µg/mL [142].
Further studies have revealed that photoexcitation of gymnochrome A (65, Figure 17B) may induce
electrophysiological effects such as the blockage of background K+ current in the atrial region of the frog
heart muscle [147]. Moreover, gymnochrome B (66, Figure 17B) has demonstrated powerful virucidal
and antiviral photoactivity with median effective dose (ED50) of 0.042 nM/mL and 0.029 nM/mL,
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In addition  to  three previously described  sulfated asterosaponins  (thornasteroside A  (72, Figure 
18B), ophidianoside F (73, Figure 18B) and regularoside B (74, Figure 18B)), which belong to a family 







































































Figure 17. (A) Gymnochrinus richeri. Postage stamp issued by the Office des Postes et Télécommunications
(1988) (courtesy of a private collection); (B) Structure of gymnochrome A (65), B (66), C (67), D (68),
isogymnochrome D (69), cholest-4-en-3-one (70) and cholesta-1,4-dien-3-one (71).
5.4.4. Thromidia Catalai
Thromidia catalai (voucher #EA065, IRD Nouméa, Figure 18A) is one of the largest known starfish
species, discovered by René Catala in the inner lagoon close to Dumbea Pass in the barrier reef of the
Southern Province, around 25 m in depth. This massive five-armed species reaches up to 60 cm in
diameter and weighs several kilograms.
In addition to three previously described sulfated asterosaponins (thornasteroside A (72,
Figure 18B), ophidianoside F (73, Figure 18B) and regularoside B (74, Figure 18B)), which belong
to a family of strong surfactants with ichthyotoxic properties, polar T. catalai extracts revealed a new
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Macroalgae  belong  to  three  different  divisions:  red  algae  (Rhodophyta),  brown  algae 
(Heterokontophyta,  also  known  as  the  Ochrophyta,  class  Phaeophyceae)  and  green  algae 
(Chlorophyta).  All  three  evolutionary  lineages  diverged  early  on  according  to  their  respective 
plastid configurations, reflecting their endosymbiotic history [150]. 
Algae  have  a  relatively  unspecialized  vegetative  apparatus  called  a  thallus.  Important 
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Despite  their  capacity  to produce  large amounts of natural products, macroalgae  from New 
Caledonia  have  been  little  documented  in  this  respect.  Caulerpa  species  were  investigated  for 
caulerpicin (76–80, Figure 19) activity in the 1980s for cosmetic purposes, but the highly publicized 
invasion of Caulerpa taxifolia  in Mediterranean Sea brought  the project  to an  immediate halt  [156]. 
The genus Lobophora  (Phaeophyta) has been  investigated  in biological  interaction studies between 
macroalgae and several corals as part of a PhD thesis. Three new compounds have been isolated and 
described [34], and their bioactivity experimentally tested on corals results in severe coral bleaching. 
Figure 18. (A) Thromidia catalai. © IRD; (B) Structure of thornasteroside A (72), ophidianoside F (73),
regularoside B (74) and thromidioside (75).
5.5. Macroalgae
Macroalgae belong t three different divisions: red algae (Rhodophyta), brown lgae
(Heterok ntophyta, also known as the Ochrophyta, class Phaeoph ceae) and green algae (Chlorophyta).
All three evolutionary lineages diverged early on according to their respective plastid configurations,
reflecting their endosymbiotic history [150].
Algae have a relatively unspecialized vegetative apparatus called a thallus. Important differences
are noted in many ultrastructural and biochemical features including photosynthetic pigments,
storage compounds, composition of cell walls, presence/absence of flagella, ultrastructure of mitosis,
connections between adjacent cells, and the fine structure of chloroplasts. They vary from small,
single-celled forms to complex multicellular forms, such as the giant kelp Macrocystis pyrifera that can
grow up to 49 m in length in New Zealand and holds the record of the fastest growing organism (0.6 m
per day).
Marine macroalgae generally live attached to r cks or other hard substrata n coastal areas but
can be also found in sandy areas such as the Udoteaceae in tropic l areas. They occu in all of the
world’s oceans where they occupy the seabed (phytobenthos), although a few species float freely on
the surface (e.g., the pelagic algae of the Sargasso Sea). In New Caledonia [151], the large brown algae
are mainly Fucales (Sargassum, Turbinaria) and Dictyotales and form large stands on rocky lagoon
bottoms, while several Chlorophyta species from the genera Halimeda and Caulerpa colonize sandy
bottoms [152–155]. The large fleshy Rhodophyta are mainly restricted to outer slopes or the cooler
waters of the southern lagoon. As of 2007, 454 species of algae and marine angiosperms had been
reported in New Caledonian waters [5].
Despite their capacity to produce large amounts of natural products, acroalgae from New
Caledonia have een little d cumented in this respect. Caulerpa species were investigat d for
caulerpicin (76–80, Figu e 19) activity in the 1980s for cosmetic purposes, but the highly publicized
invasion of Caulerpa taxifolia in Mediterranea Sea brought the projec to an immediate halt [156].
The genus Lobophora (Phaeophyta) has been investigated in biological interaction studies between
macroalgae and several corals as part of a PhD thesis. Three new compounds have been isolated and
described [34], and their bioactivity experimentally tested on corals results in severe coral bleaching.
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5.6. Microalgae and Cyanobacteria
Less than 1% of described marine phytoplanktonic species are known to produce potent
toxins [157]. Microalgal benthic dinoflagellates species are involved, including Gambierdiscus toxicus
that produces maitotoxin (81, Figure 20). In vivo toxicity in mice indicates that intraperitoneal injection
of 0.13 µg/kg is lethal [158]. A culture of ca. 4000 L of dinoflagellate cells is needed for the purification
of 20 mg of MTX, enough to kill about four million mice. MTX activates both voltage-sensitive and
receptor-operated calcium channels in the plasma membrane, thus inducing calpain protease that
rapidly leads to cell death. MTX has since been considered as a useful tool for investigating the
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Figure 20. Structure of maitotoxin (81).
Species belonging to the genus Gambierdiscus have also been shown to produce ciguatoxin
analogues (CTX analogs) causing ciguatera fish poisoning (CFP). New Caledonia is a CFP-endemic
area. CFP constitutes a global health problem with more than 50,000 people worldwide affected by
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this disease annually. CTXs arise from biotransformation/metabolization of CTX analogs through
the food chain: from herbivorous fish that accumulate dinoflagellate toxins by eating dead coral and
marine algae to carnivorous fish [157]. In Pacific areas, the principal and most potent CTX is Pacific
ciguatoxin-1 (82, Figure 21). CTXs are potent activators of voltage-sensitive sodium channels and cause
an increase in neuronal excitability and neurotransmitter release [160]. In New Caledonia, traditional
remedies are commonly employed in the treatment of CFP: 90 plant species have been catalogued
as useful CFP remedies, including the leaves of Heliotropium foertherianum used to prepare the most
popular herbal remedy [161].
A study conducted by D. Laurent et al. following the observation of many cases of seafood
poisoning on Lifou Island between 2001 and 2005 (Loyalty Islands, New Caledonia, Figure 1), indicates
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instigated  by  IFREMER‐New  Caledonia,  the  Physiology  and  Biotechnology  of  Algae  (PBA) 
laboratory  (Nantes,  mainland  France)  and  ADECAL  (Caledonian  Economic  Development 
Agency‐Nouméa,  [164]),  aims  to  develop  industrial microalgal  production  based  on  indigenous 
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Figure 21. Structure of Pacific ciguatoxin-1 (P-CTX-1) (82).
In line with pr grams explo ing the biodiversity of planktonic species such as OCEANOMICs
(see [162] for details), the project AMICAL (Aquaculture of MIcroalgae in New CALedonia, [163])
instigated by IFREMER-New Caledonia, the Physiology and Biotechnology of Algae (PBA) laboratory
(Nantes, mainland Fran e) and ADECAL (Caledo ian Economic Development Agency-Nouméa, [164]),
aims to develop industri l microalgal production bas d on indigenous microalgae species isolated
along the mainland coasts (Figure 1). Partners of this program will transfer the cultivation and
extraction techniques to selected algal species for industrial programs in New Caledonia targeting the
animal nutrition market nd high added-value compounds (cosmetics, health food, etc.).
5.7. Other Biological Sources
Statistically “minor” phyla in terms of the number of studies on local species include prokaryotes,
several invertebrate phyla, and snakes as the sole vertebrate representatives.
5.7.1. Prokaryotes and Fungi
Micrococcus Luteus
Micrococcus luteus is a Gram+ bacterium that was isolated from Xestospongia exigua sponges
collected off Nouméa in the Southwest Pacific. Chemical studies reveal that this bacterium can
produce lutoside (83, Figure 22), an acyl-1-(acyl-61-mannobiosyl)-3-glycerol, and also triclosan (84,
Figure 22) (2,4,41-trichloro-21-hydroxydiphenylether), with both molecules presenting antibacterial
activities [165,166].
Bacteria from Pseudoalteromonas and Vibrio Genus
Along the west coast of New Caledonia, 205 environmental samples were collected on a variety
of surfaces (sediments, intertidal rocks, invertebrates, plants, fish and biofilms found on organic
substrates). This sampling led to the isolation of 493 marine bacteria [167,168]. Studies were at first
performed to assess their ability to produce exopolysaccharides (EPSs). Among them, the new strain
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Vibrio neocaledonicus sp. nov. (NC470), isolated from a biofilm found on Holothuroidea in St. Vincent
Bay, has demonstrated the production of EPSs that have a high N-acetyl-hexosamine and uronic acid
content with a low amount of neutral sugars. Preliminary experiments conducted on these EPSs
have shown high metal-binding capacity [167]. Further studies have shown that four other strains
(NC282, NC412, NC272 and NC120), which belong to the genus Pseudoalteromonas, have antibacterial
potential against reference and multidrug-resistant pathogen strains such as Staphylococcus aureus,




















a  new  cytotoxic  metabolite  sesquiterpene  trichothecene,  along  with  known  trichothecenic 
mycotoxins (e.g., verrucarine A (86, Figure 23),  isororidine A (87, Figure 23) and some previously 
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Figure 22. Structure of lutoside (83) and triclosan (84).
Acremonium Neocaledoniae
The culture of the marine fungus Acremonium neocaledoniae (moniliaceae), collected on driftwood
in the southwestern lagoon of New Caledonia, led to the production of verrol 4-acetate (85,
Figure 23) [169], a new cytotoxic metabolite sesquiterpene trichothecene, along with known
trichothecenic mycotoxins (e.g., verrucarine A (86, Figure 23), isororidine A (87, Figure 23) and
some previously described styrylpyrones, such as kawain (88, Figure 23), 7,8-dihydrokawain (89,
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Figure 23. Structure of verrol 4-acetate (85), verrucarine A (86), isororidine A (87), kawain (88),
7,8-dihydrokawain (89) and 5,6-dehydrokawain (90).
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5.7.2. Venomous Cone Snails
Venomous marine cone snails (Conoidea) are neogastropod mollusks that predate on marine
worms and small benthic invertebrates (thick-shelled snails, e.g., Conus textile) or that actively
“hunt” fish (thin-shelled snails, e.g., Conus geographus) primarily by inflicting cocktails of peptide
neurotoxins produced by venom glands via their modified harpoon-like radula (see review in Kaas
and Craik, 2014 [171]). Fish-hunting cone snails may switch from prey-stimulated to defensive
envenomation strategies as shown by the use of different and more potent “high threat” neurotoxins if
threatened, the latter being regarded as a specialization in response to predation pressure from
fish and cephalopods [172]. In addition, C. geographus (common in New Caledonia) diffuses a
“cloud” of fish-like insulin that literally "tetanizes" the fish by eliciting hypoglycemic shock prior
to envenomation [173], a possible metabolic cost-saving feature. Pharmacological applications of
cone snail venoms have stemmed from the work of Olivera’s group on Conus magus, which inspired
the biosynthesis of the most potent pain-killer on the market (ziconotide, Prialt®, Dublin, Ireland),
claimed to be 1000 times more potent than morphine for the sedation of terminally ill cancer patients.
The CONCO cone snail genome project for health funded by the European Commission was launched
in 2005 to study the toxins composing the venom of the cone snail Conus consors (Figure 24) from the
Chesterfield Islands using genomic, transcriptomic and proteomic approaches. The mitochondrial
genome of C. consors has now been sequenced and gene annotated. The authors report the presence of a
novel 700 bp control region absent from the hitherto known mitochondrial genomes of cone shells [174].
The species richness of venomous cone mollusks in New Caledonia is exceptional and prompts further
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Figure 24. Conus consors. Photo Jan Delsing [175]. Figure 24. Conus consors. Photo Jan Delsing [175].
5.8. Vertebrates: Venomous Marine Snakes
Globally, snake venom studies are of primordial importance for the design of novel antivenoms,
for research tools in neurophysiology, and for a better understanding of the adaptive history of reptiles.
Like Australia, New Caledonia has no terrestrial venomous snakes, and Gail and Rageau
established the first census of venomous marine snakes from the Elapidae family in 1955 [176]. Of the
marine snakes that have been investigated by toxicologists, the most common ones are Laticauda
laticaudata and its congener Laticauda colubrina, both highly venomous snakes that essentially hunt
small fish underwater at night and rest on land during the day (Figure 25A).
L. laticaudata and L. colubrina rank, respectively, 9th and 46th among the 163 most venomous
snakes (terrestrial and marine species of all continents). Being related to well-known Asian cobras
and African mambas (Elapidae), but being much easier to handle (the mouth is very small and the
hooks are adapted to bite prey during the swallowing process), laticaudas are an excellent model
for toxicologists. A major component, erabutoxin b (91, Figure 25B) from Laticauda semifasciata
binds with high affinity to muscular nicotinic acetylcholine receptors (nAChRs), but with low
affinity to neuronal alpha-7 nAChRs and inhibits acetylcholine from binding to the receptor, thereby
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impairing neuromuscular transmission [177]. As a result, it produces peripheral paralysis by blocking
neuromuscular transmission at the postsynaptic site. The first cDNA studies undertaken as part of a
collaboration between the Centre d'Etudes Nucléaires de Saclay and Tokyo University [178] later included
New Caledonian snakes in a review of the evolution of Elapid snake venoms [179].
Aipisurus laevis is a fully pelagic species, collected in surface waters of the lagoon in the Southern
Province. A. laevis ranks 10 out of the 163 known most “globally dangerous” snakes, and 30 out of 163
in terms of toxicity (LD50 by injection in mice). Two cDNAs of short-chain neurotoxins were cloned
and sequenced by Ducancel et al., (1990) [180], and compared with similar work on erabutoxin b (91,
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Figure 25.  (A) Laticauda colubrina and Laticauda laticaudata. Postage stamps  issued by  the Office des 
Postes  et Télécommunications  (1983)  (courtesy  of  a  private  collection);  (B) Amino‐acid  sequence  of 






after  promising  results  were  revealed  by  preliminary  biological  screening  and  spectral 
characterization,  further  biological  and  chemical  investigations  on  several molecules  have  been 
pursued to carry out (i) total synthesis; (ii) synthesis of chemical derivatives selected on the basis of 




Figure 25. (A) Laticauda colubrina and Laticauda laticaudata. Postage stamps issued by the Office des Postes
et Télécommunications (1983) (courtesy of a private collection); (B) Amino-acid sequence of erabutoxin b
(91). Half cysteine residues are noted in red. One-letter codes for amino acids: C, cysteine; D, aspartate;
E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; N, asparagine;
P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine.
Adapted from [179].
6. Recent Advances on Selected New Caledonian Marine Natural Products
Following their discovery in the course of ongoing New Caledonian scientific programs, and after
promising results were revealed by preliminary biological screening and spectral characterization,
further biological and chemical investigations on several molecules have been pursued to carry out
(i) total synthesis; (ii) synthesis of chemical derivatives selected on the basis of structure-activity
relationship (SAR) studies; (iii) determination of the mechanism of action; (iv) determination of
additional bioactivities including in vivo and receptor studies. These studies and relevant updates are
listed in Table 6.
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Table 6. Subsequent and ongoing development of selected natural products isolated from New Caledonian marine organisms.
Natural Product and/or Analogs Chemical Synthesis and Biological Activity Reference
(´)-agelastatin A–F
-Enantioselective total synthesis involving late-stage C-ring formation.
-(´)-agelastatin A: antiproliferative activity highly potent on blood cancer cell lines (CEM EC50 20 nM; Jurkat EC50
74 nM; Daudi EC50 20 nM; HL-60 EC50 138 nM; CA46 EC50 187 nM) vs. normal red blood cells (EC50 > 333 µM);




-In vitro and in vivo antiproliferative activity: CLL patient (CLL1 and CLL2) and JVM-2 cell line (EC50 0.064 µM and
0.16 µM respectively).
-Chemical modifications outside the pyrrole ring result in significant loss in activity.
-Importance of an electronegative functional group at position C-13 for CLL activity.
[182]
suvanine
-Anti-inflammatory activity, Hsp 60 inhibitor. [183]
-Antagonist of farnesoid-X-receptor (FXR).
-Identification of conformational changes responsible for agonist/antagonist form on FXR using suvanine
as template.
[184]
-Inhibitor of hepatitis C virus NS3 helicase (IC50 of 3 µM).
-Inhibition of ATPase, RNA binding, and serine protease activities of NS3 helicase with IC50 7, 3, and
34 µM, respectively.




-Inhibition of CLK kinases (hymenialdisine only). [186]
-Stimulation of translation: isohymenialdisine and hymenialdisine act on PKR (RNA-dependent protein kinase) by
inhibiting its autophosphorylation and pertub the PKR-eIF2α phosphorylation axis; models indicate that it fits in
the PKR ATP binding site.
[187]
-Short (6 steps), concise, and high yielding (44%) total synthesis of hymenialdisine will enable the synthesis of
novel libraries for subsequent SAR studies. [188]
arsenicin A
-Synthesis of sulfur-derivatives.
-Antiproliferative activity of monosulfide (˘)-arsenicin A (more potent on APL cells than (˘)-arsenicin A and




-Targets TDP-43, binds to specific sequences on DNA and RNA. [191]
-Antiproliferative (A498 EC50 1.57 µM).
-Induction of both apoptosis and autophagy (heteronemin inhibits the phosphorylation of ERK and AKT signaling
pathways and increases the phosphorylation of p38 and JNK).
[192]
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Table 6. Cont.
Natural Product and/or Analogs Chemical Synthesis and Biological Activity Reference
bengamides and analogs
-Synthesis of novel caprolactam-ring-opened bengamide analogs with antitumor activity on MDA-MB-435
(compounds 3a (EC50 4 nM) and 2i (EC50 9 nM) more potent activity than LAF389, analog of bengamide (EC50 40
nM) and the original caprolactam analog 10’ (EC50 17 nM).
-Improved water solubility.
[193]
Methionine aminopeptidases inhibitors (HsMetAP1 and HsMetAP2). [194]
-Synthesis of a series of inhibitors of methionine aminopeptidases of Mycobacterium tuberculosis.
-New X-ray structures of MtMetAP1c in complex with inhibitors in Mn(II) and Ni(II) forms; all amide moieties bind
to the unique shallow cavity and interact with flat surface created by His-212 of MtMetAP1c in the Mn(II) form.
Influence of active site metal on binding mode (amide takes on a different conformation in the Ni(II) form).
[195]
-Analogs of bengamide E with antiproliferative properties (modified at the terminal olefinic position).
-More potent activity: compound 56 (a cyclopentyl group replaced the isopropyl group at the terminal
olefinic position).
[196]
-Synthesis of stereoisomers of bengamide E (2,3-bis-epi- and the 2-epianalogues), a collection of C2-modified
analogues, and various epoxy bengamides.
-Stereochemistry at C2 and C3 positions and methoxyl group at C2: essential for retaining the cytotoxic potency.
[197]
naamidine A -Antitumor agent; induction of apoptosis (caspase-dependent). [198,199]
microsclerodermin A
-Inhibition of NFκB transcriptional activity, reduced levels of phosphorylated (active) NFκB in the AsPC-1 cell line.
-Antiproliferative activities: AsPC-1, BxPC-3, MIA PaCa-2 and PANC-1 pancreatic cancer cell lines.
-Induction of apoptosis in the AsPC-1 mediated by GSK-3β pathway.
[200]
petrosaspongiolide M and analogs
-Synthetic derivative of benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one.




-Inhibitory activity by binding the active sites in the inner core of the immunoproteasome and/or covalently
linking a Lys residue at the proteasome core/11S activator particle interface.
-Modulation of intracellular proteolysis through a dual inhibition of the immunoproteasome and autophagy.
[202]
aeroplysinin-1
-Induction of apoptosis in endothelial cells (caspase dependent). [203]




fistularin-3 -Antiproliferative activity dose- and time-dependent (EC50 7.39 and 8.10 µM for Jurkat E6.1 and U937 resp.);Pro-apoptotic. [205]
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Table 6. Cont.
Natural Product and/or Analogs Chemical Synthesis and Biological Activity Reference
Analogs of bistramide A
-Design and synthesis of analog of bistramide A targeting cytoskeletal organization of cancer cells in vivo
(combination of reversible G-actin binding and effective F-actin severing).
-Potent and reversible binding of monomeric actin (Kd 9.0 nM), in vitro depolymerization of actin; in vitro and
in vivo inhibition of A549 cells.
[206]
-Computational analyses of non-covalent actin-inhibitor interactions (AutoDock and DrugScore scoring function).
-Design of a novel, highly modular class of hybrid analogs with a rationale to address both the bistramide and
rhizopodin binding sites.
-Antiproliferative activity is conserved in analogs resembling the original side chain of rhizopodin.
[207]
luzonicoside A -Potent immunomodulatory agent: more effective in stimulating lysosomal activity, intracellular ROS levelelevation, and NO synthesis up-regulation in RAW 264.7 murine macrophages cells (0.01–0.1 µM). [208]
Cell lines: CEM human acute lymphoblastic leukemia, Jurkat human T leukemia, Daudi human B lymphoma (Burkitt’s lymphoma), HL-60 human acute promyelocytic leukemia,
CA46 human lymphoma (Burkitt’s lymphoma), CLL chronic lymphocytic leukemia, JVM-2 human lymphoma (Mantle Cell Lymphoma), APL acute promyelocytic leukemia, A498
human kidney carcinoma, MDA-MB-435 human breast adenocarcinoma, AML acute myeloid leukemia, AsPC-1, BxPC-3, MIA Paca-2, PANC-1 pancreatic cancer cell lines. Proteins:
Hsp-60 Heat shock protein 60, FXR farnesoid X receptor, NS3 nonstructural protein 3, CLK protein kinases, PKR protein kinase R, TDP-43 TAR (trans-activator regulatory) DNA-binding
Protein 43, ERK extracellular signal-regulated kinase, AKT protein kinase B, JNK c-Jun N-terminal kinase, GSK-3β glycogen synthase kinase-3β, STAT3 signal transducer and activator
of transcription. Virus: HCV hepatitis C virus. Others: SAR structure-activity relationship, NO nitric oxide.
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Despite recent advances in developing therapeutic strategies, cancer is still one of the leading
causes of death worldwide. Cancer is a group of diseases characterized by the uncontrolled growth
and spread of abnormal cells. Drug-induced programmed cell death holds promise for cancer
therapeutic approaches. Apoptosis is one of the well-known pathways used by cells to die. It is
a morphological event characterized by chromosomal DNA fragmentation, nuclear disintegration,
cell shrinkage, translocation of phosphatidyl serine moieties to the outer membrane leaflet, and
membrane blebbing [209]. Numerous anticancer drugs, both on the market and in development,
have apoptosis-modulating properties (e.g., Yondelis®, Madrid, Spain, has been recently approved
by the American Food and Drug Administration (FDA) to treat patients with advanced soft tissue
sarcoma [210]). Apoptogens are agents that can induce rapid death by modulating the apoptosis
pathway. Numerous marine natural products reported in Table 6 are apoptogenic compounds
associated with antitumor activity.
Agelastatins, members of the chemically diverse pyrrole-imidazole alkaloids (PIA), are among
the best examples of this class of molecules. Since the discovery of agelastatin A (92, Figure 26) in
1993 by Pietra et al., in the New Caledonian coral sea sponge Agelas dendromorpha, more than ten
different research groups have reported innovative solutions to synthesize it. As reported in Han et al.,
2013, recent development of a concise, stereo-controlled, and biosynthetically inspired strategy to
synthesize agelastatin alkaloids and a new synthetic methodology for azaheterocycle synthesis has
given rise to many agelastatin derivatives. These developments also facilitate the first side-by-side
testing of all known agelastatin alkaloids for their ability to induce cell death in various cancer
cells [181]: U-937 (lymphoma), HeLa (cervical carcinoma), A549 (non-small-cell lung carcinoma),
BT549 (breast carcinoma), and IMR90 (immortalized lung fibroblasts) human cell lines. Agelastatins
A (92, Figure 26) and D (95, Figure 26) both induce dose-dependent apoptosis (in particular cell
membrane permeabilization, activation of procaspase-3 to active caspase-3 and proteolytic cleavage
of poly(ADP-ribose) polymerase (PARP)) and exhibit dose-dependent G2/M cell cycle arrest in
synchronized U-937 cells without affecting tubulin dynamics within cells [181]. In addition, the
potency of all agelastatins (92–97, Figure 26) has been evaluated in five human blood cancer cell lines.
Interestingly, agelastatin C (94, Figure 26) is only weakly active and agelastatin F (97, Figure 26) is
inactive against the tested cell lines. Agelastatin A (92, Figure 26) is remarkably active, particularly
against CEM from acute lymphoblastic leukemia and against Daudi from Burkitt’s lymphoma (values
reported in Table 6) and specifically target these white blood cell lines over normal red blood cells: it is
16,650 times more active on cancer cells than on normal cells! These results are in line with a previous
study showing the inhibition of osteopontin-mediated neoplastic transformation (notably by β-catenin
inhibition) and metastasis by agelastatin A (92, Figure 26) in MDA-MB-231 and MDA-MB-435 human
breast cancer cell lines [211]. Therefore, agelastatins exhibit considerable potential as antitumor drugs
that can simultaneously inhibit cancer cell growth as well as act as a potent anti-metastatic drug [211].
However, the mechanism through which agelastatin A (92, Figure 26) causes this cellular effect,
particularly cycle arrest, still needs to be elucidated. Identification of potential intracellular targets of
agelastatins can be performed by affinity chromatography on immobilized agelastatin. This approach
has previously provided valuable insights into the cellular targets of various protein kinases inhibitors
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Figure  26. Structure of agelastatin A–F  (92–97), 13‐debromo‐13‐trifluoromethyl agelastatin A  (98), 
suvanine  (99),  isohymenialdisine  (100),  monosulfide  arsenicin  A  (101),  heteronemin  (102), 
bengamide  E  (103)  and  analogs:  2,3‐bis‐epi‐bengamide  E  (104),  2‐epi‐bengamide  E  (105)  and 
3,4‐bis‐epi‐bengamide E (106), naamidine A (107), microsclerodermin A (108), petrosaspongiolide M 
(109),  natural  analogs  of  petrosaspongiolide  M  (110–112),  first  generation  of  synthetic 
petrosaspongiolide  M  analogs  (113–120),  second  generation  of  synthetic  petrosaspongiolide  M 
analogs  (121–126),  aeroplysinin‐1  (127),  fistularin‐3  (128),  analogs  of  bistramide A  (129),  adapted 
from [206] and luzonicoside A (130). 
Among the molecules reported in Table 6, heteronemin (102, Figure 26), a marine sesterterpene, 
has  been  shown  to  induce  apoptosis  in A‐498  human  renal  carcinoma  cells  by  downregulating 
apoptosis  inhibitors  Bcl‐2  and  Bcl‐xL  and  upregulating  the  death  agonist  Bax,  leading  to  the 
disruption  of  the  mitochondrial  membrane  potential  and  the  release  of  cytochrome  c  from 
mitochondria [192]. As also reported for agelastatins, these effects are associated with the activation 
of  caspases  (3/8  and  9),  followed  by PARP  cleavage.  Interestingly,  the  same  study  showed  that 
heteronemin (102, Figure 26) also induces autophagy in A‐498 cells, but the inhibition of autophagy 
enhances the anticancer effect of heteronemin (102, Figure 26) in A‐498 cells. This result suggests that 
the  combination  of  heteronemin  (102,  Figure  26) with  autophagy  inhibitors  further  enhances  its 
therapeutic effects for cancer treatment [192]. Therefore, marine molecules can represent chemical 
tools for the exploration of novel combined therapeutic strategies. Petrosaspongiolide M (109, Figure 26) 
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chemically  modified  to  become  drugs  [215,216].  The  four  other  molecules  underwent  lead 
Figure 26. Structure of agelastatin A–F (92–97), 13-debromo-13-trifluoromethyl agelastati (98),
suvanine (99), isohymenialdisine (100), monosulfide arsenicin A (101), heteronemin (102), bengamide
E (103) and analogs: 2, -bis-epi-bengamide E (104), 2-epi-bengamide E (105) and 3,4-b s-epi-bengamide
E (106), naam dine A (107), microsclerodermin A (108), petrosaspongiolide M (109), natural analogs
of petrosaspongiolide M (110–112), first generation of synthetic petrosaspongiolide M a alogs
(113–120), seco d gen ration of synthetic petrosaspongiolide M analogs (121–126), aeroplysinin-1
(127), fistularin-3 ( 8), nalogs of bistramide A (129), adapted from [206] and luzonicoside A (130).
Among the molecules reported in Table 6, heteronemin (102, Figure 26), a marine sesterterpene,
has been show to induce apoptosis in A-498 human renal carci oma cells by downregulating apo tosis
inhibitors Bcl-2 and Bcl-xL and upregulating the death agonist Bax, leading to the disruption of the
mitochondrial membrane potential and the release of cytochrome c from mitochondria [192]. As also
reported for agelastatins, these effects are associated with the activation of caspases (3/8 and 9),
followed by PARP cleavage. Interestingly, the same study showed that heteronemin (102, Figure 26)
also induces autophagy in A-498 cells, but the inhibition of autophagy enhances the anticancer
effect of heteronemin (102, Figure 26) in A-498 cells. This result suggests that the combination of
heteronemin (102, Figure 26) with autophagy inhibitors further enhances its therapeutic effects for
cancer treatment [192]. Therefore, marine molecules can represent chemical tools for the exploration
of novel combined therapeutic strategies. Petrosaspongiolide M (109, Figure 26) may also represent
an equally valuable chemical tool for its capacity to modulate intracellular proteolysis through dual
inhibition of the immunoproteasome and autophagy [202].
Synergistic effects (e.g., treatment with heteronemin (102, Figure 26) and inhibitors of autophagy
such as chloroquine) of marine products and therapeutic drugs on disease-related phenotypes
highlight the concept of combination therapy. The cytotoxicity of new marine molecules should
be tested alone or in combination with known anticancer compounds to overcome drug resistance, as
repo ted in Elm llah and Micheau (2015) for the resistance of cancer cell to TNF-related apoptosis
inducing lig n (TRAIL)-induced cell death [209]. TRAIL is a molecule that selectively kills—via
apoptosis—transformed and cancer cells, but not most normal cells [213]. Manzamine A, an alkaloid
originally isolated from an Okinawan sponge Haliclona sp., may re t re TRAIL-i duced poptotic
cell death in the TRAIL-resistance pancreatic AsPC-1 cell line via inhibition of glycogen sy thase
kinase-3β (GSK-3β) and subsequent inhibition of the survival factor NF-κB [209]. It will thus be very
interesting to evaluate the TRAIL-sensitizing activity of agelastatin A (92, Figure 26); which is known
to inhibit GSK-3β with an IC50 of 12 µM [44] (manzamine A has an IC50 for GSK-3β inhibition of
10 µM [214]). All new marine natural products, including those from biodiversity hotspots such as
the New Caledonia archipelago, represent putative new hope for cancer treatments, in particular for
overcoming defects in apoptosis signaling.
As highlighted above, targeting apoptotic pathways may have a direct role in inducing tumor cell
death, as confirmed by recent advances on marine molecules found in New Caledonia. In addition
to agelastatins and heteronemin (102, Figure 26), naamidine A (107, Figure 26), microsclerodermin
A (108, Figure 26), aeroplysinin-1 (127, Figure 26), fistularin-3 (128, Figure 26) have been shown
to induce apoptosis (Table 6). Cancer is the principal target of the marine molecules released on
the market today. Of the seven marine compounds currently on the market, only three (Prialt®,
Dublin, Ireland; Yondelis®, Madrid, Spain and Lovaza®, London, UK) were not chemically modified
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to become drugs [215,216]. The four other molecules underwent lead optimization during the various
different stages of their development. Developments in structural chemistry must be followed by the
characterization of biological targets to optimize therapeutic applications.
7. Conclusions
Though far from being exhaustive, this review outlines 40 years of exciting research on the
chemodiversity of marine organisms, ranging from microbes and invertebrates to vertebrates, from
microalgae to macroalgae and halophytes, belonging to very different biota in association with the
complex coral reef systems of New Caledonia.
Traditionally “interesting” lead groups such as sponges, cnidarians and ascidians have been
intensely investigated because they not only provide the most interesting array of original chemical
structures, but they also show the most potent anticancer, anti-inflammatory and antibiotic properties.
Other groups have occasionally led to original and stimulating research: echinoderms, mollusks,
etc. This review focused on novel products although several studies have been performed on New
Caledonian marine species leading to the rediscovery of some secondary metabolites (e.g., Acremonium
neocaledoniae, p. 41).
The fact that “minor” groups have been largely left aside does not reflect their lack of intrinsic
interest for chemical exploration, but rather the technical difficulties to collect or cultivate them in
New Caledonia. Only about 2% of marine bacteria can be cultivated using classical growth media.
Some small invertebrates require time-consuming field and laboratory work to get enough molecular
material to work on (e.g., bryozoans), are haphazardly encountered (e.g., many “naked” nudibranch
and opistobranch mollusks) or are on an endangered species list, etc. Noteworthy are independent
investigations on different models: e.g., biomaterials from scleractinian corals for maxillofacial
replacement of bone tissue [217] or from oyster nacre as an osteoinductor in odontology [218].
Another example is that of the endemic Nautilus macromphallus cephalopod excretory metabolism. This
metabolism relies on a unique and seemingly very stable symbiosis with specific bacterial symbionts
to produce molecular nitrogen in the chambered shell and regulate the buoyancy [219].
Figure 2 indicates that the “golden age” of traditional screening for novel molecules and bioactivity
has ceased after several periods of intense investigation. This reflects the successive explorations of
new “territories”, e.g., sea mounts, outer reef slopes and deep benthos in general. Based on what has
been achieved thus far, taking into account the exceptional richness of the local biota and the growing
need to develop local economy in a balanced and sustainable way, it appears necessary to develop a
permanent, reliable and collaborative research and development pipeline linking field exploration to:
-drug development, including (i) isolation of active principles; (ii) high-throughput bioactivity
screening; (iii) structure-activity investigations and structural elucidation; (iv) cultivation
technologies or bioinspired synthesis; (v) clinical trials and beyond;
-aquaculture focusing on the treatment of locally grown species of prawns and oyster varieties that
are sensitive to seasonal blooms of toxigenic bacteria and microalgae.
Molecular approaches have now come of age, making new biological models more attractive and
promising. New Caledonia represents a living laboratory with its unique source of marine organisms
that have not been investigated to date. There is now a need to better understand the relationships
between host organisms and their microbial flora. This requires on-site operations and specialized
equipment (aquaria, cultivation facilities for microorganisms).
Finally, in the general context of “blue growth”, New Caledonia is ideally located for investigating
the production of third-generation biofuels and of high value-added products (e.g., cosmetics,
nutraceuticals) via the biomass of microalgal primary producers.
New Caledonia is a treasure chest for scientists to explore, but is also fragile. With the perspective
of climate change due to global warming and emerging anthropogenic forcings, the sustainability
of the sources of molecules, including resident bacteria, must take precedence. New Caledonian
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coral reefs—of which some portions were added to UNESCO’s World Heritage list in 2008—must be
protected for the livelihood of resident populations, as well as for biological inspiration for the sciences
and the arts. Extensive studies of their chemodiversity should contribute to their protection.
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